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A. Abstract 
Patients requiring heart valve replacement surgery due to rheumatic or congenital 
heart valve disease have the option of receiving either a mechanical valve, a 
homograft human cadaver or a chemically treated bioprosthetic heart valve from 
animal tissue. Each valve has its limitations. The latter has a limited lifespan in 
younger patients with calcification the major cause of failure. Recently the 
significance of inflammatory response to these valves has been highlighted as well 
as the role that it may play in calcification and therefore contributing to the failure of 
these valves. 
This research was firstly directed to characterise the immune response to 
bioprosthetic heart valves in patients as well as in animal models. The study further 
demonstrated that the glutaraldehyde concentration applied to commercial heart 
valves is insufficient to mask the antigenicity of the tissue, therefore an method of 
masking antigens to mitigate the inflammatory response is needed. 
Rabbits were immunised with porcine aortic wall, decellularised porcine aortic wall 
and porcine plasma fibronectin. Tissue specific immunoglobulin was isolated and the 
Fc fragment removed to produce immunoglobulin fragments which were used to 
mask porcine aortic tissue against Fc receptor mediated adherence inflammatory 
cells. 
The finding of this thesis was that bioprosthetic heart valve tissue elicits an immune 
response in patients and animal models. The concept of applying antigen-directed 
antibody fragments to porcine aortic tissue clearly was shown to mask the antigens 
and mitigate binding of intact antibodies to the tissue in vitro. A rabbit pilot in vitro 
study did not show a clear benefit when the antibody fragments were tethered onto 
the tissue. The in vitro results were nevertheless encouraging and its potential 
should still be further investigated. 
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B. Introduct ion 
B1 . Heart Valves 
The heart conSists of four chambers wrth a valve at evefY eXit of the chamber, 
namely the aortiC. pulmonary, mitral and tocuspid valvM whICh are Msentlal to the 
physiological functioning Of the hean These valves (see figure B· l) permrt 
unld lre<:hona l flow 01 blood through Ihe heart wlthoul ObSlruchon or regurgitatIon 
The valve funcllon IS pressure droven lMlen the blood pressure below the valve IS 
greater than the pressure above the leaflets are forced towards the outs.de t<lu$lllg 
the valve to open When the blood pressure above the valve t5 "reater than the 
pressure below the vawe closes by pushll1g the leaflets toward the centre Blood 
f lows from the body anto the nght atnurn through Ihe open tncusPld valve (vel'ltncular 
re laxation) II'1to Ihe nghl ventncle The pulmonary valve opens (ventncul., 
conlraCllon) and the blood " pushed Into the pulmonary trunk towards the lungs 
The left atrium re<:e,ves the 0l<Ygenated blood from the lungs and the blood flows 
through the open mitral valve (ventncular relaxation) 11'110 Ihe left ventncle The aortic 
va lve opens (ventncular contractIOn) and the oxygenated blood IS pushed InlO the 
aorta and flows to the rest of the body 
Figure B-1 Anatomy of the heart 
" 
81.1. Anatomy of Heart Valves 
The aortic valve has cup-like leaflets composed of thin sheets of soft tissue anchored 
in the aortic wall. A cross-section of the leaflet shows three distinct layers 1 (see 
figure 2), each with specific extracellular matrix components. The top layer of the 
leaflet on the outflow side is the fibrosa2, which is composed of densely packed 
collagen bundles and fibres with a matrix of elastin surrounding the collagen bundles. 
It is the primary structural layer that provides strength and prevents the leaflet from 
sagging. The layer on the inflow side is the ventricularis2. This layer has dense 
collagen with elastic fibres and is less stiff than the fibrosa, allowing the leaflet to 
stretch when closed3• The middle layer connecting the fibrosa and ventricularis 
together is the spongiosa. This layer is composed of loosely arranged collagen and 
abundant glycosaminoglycans. The glycosaminoglycans are capable of absorbing a 
large amount of water within the tissue matrix. This matrix serves to decrease the 
shear stresses associated with continuous bending, rearranging, straightening, and 
rotating during valve function4-1o. The valvular interstitial cells such as fibroblasts, as 
well as endothelial cells and resident macrophages are present in abundance in the 
valve tissue. Fibroblasts synthesise the several types of valvular extracellular matrix 
molecules. The valve undergoes constant physiological remodelling that entails the 
synthesis, degradation, and reorganization of its extracellular matrix11. 12. Thus, heart 
valves are specialised components of the heart that rely on balanced homeostatic 
activities for their mechanical and biological functions. 
0.3 - 0.7 mm 
thickness 
Collagen I Elastin 
Glycosaminoglycans 






Figure B-2 Schematic cross-section of the leaflet 
81.2. Pathology 
Heart valve diseases are typically associated with either acquired calcific disease, 
degeneration of congenitally abnormal valves, atherosclerosis, infections 
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(endocarditis), or rheumatic heart disease and results in progressively defective 
valves12. Valve dysfunction limits the valves to open and close properly. This results 
in imperfect closure, permitting back flow (insufficiency or regurgitation) or 
incomplete opening, limiting forward blood flow (stenosis) or both. Either process 
critically influences the performance of the heart, possible hampering the heart's 
ability to pump blood adequately through the body. Damaged heart valves lack the 
ability to spontaneously regenerate13 and the only treatment option presently 
available is open-heart surgery, in which the diseased valve is either repaired or 
removed and replaced with a prosthetic one. Endovascularly deployed valves may 
offer and alternative to open-heart surgery, but would similarly rely on the 
introduction of a tissue based valve prosthesis. 
82. Prosthetic heart valves 
Heart valve disease is a worldwide problem and ultimately leads to most patients 
with the disease needing heart valve replacement surgery. It entails surgical removal 
of the diseased valve and suturing in its place a prosthetic valve made of non-living, 
biocompatible biomaterials to resume valvular mechanical functions. Heart valve 
replacement is often lifesaving and improves reCipient's quality of life14. The first 
heart valve replacements performed in 1960 were mechanical devices 15, 16. In 1962 
the first biological heart valve was used when Ross replaced an aortic valve with a 
freeze-dried valve from human cadavers (homograft) 17, and in 1965 the first 
bioprosthetic valves from porcine aortic tissue were Used18. The porcine prosthesiS 
was the valve of choice in the 1970s and early 1980S19. However, the increasing 
incidence of structural valve degeneration of these porcine valves20, 21 resulted in an 
increased used of mechanical valves22 with biological valves being limited to patients 
in whom anticoagulation was contraindicated or to elderly patients 14, 19, 23. The 
second generation of tissue valves improved their durability, but structural valve 
degeneration was still the limiting factor. Worldwide, over 275,000 heart valve 
replacement operations are performed annuallf4. Presently. over 50% of implanted 
prosthetic heart valves are mechanical valves, approximately 45% are bioprosthetic 
valves and the remainder are pulmonary autograft valves and human cry 0 preserved 
homografts25. The use of mechanical heart valves is increasing at a rate of 3 - 5 % 
per year compared to bioprosthetic heart valves increasing at 8 - 11 %26. 
The ideal replacement valve should have the following charactelistics27-29: 
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• Replicate the function of the natural valve, have good hemodynamic 
performance, open to allow unimpeded flow and close preventing 
regurgitation, and have limited resistance to blood flow while moving; 
• Include living cellular components with the ability to repair structural injury, 
renewal of the cell population; remodel the extracellular matrix, and 
potentially grow; 
• Be biocompatible, non-immunogenic, non-inflammatory, non-calcifying 
and with a substrate not supportive of infections; 
• Have non-thromobogenic blood-contacting surfaces; 
• Be chemically stable, non-leachable, and with non-cytotoxic components; 
• Provide ease of implantation using minimally invasive surgery and integration 
into host tissue with minimal host healing response; 
• Be durable to withstand 40 million cardiac cycles each year, resistant to wear 
and maintain structural properties throughout lifetime; 
• Ensure that the patient's daily activities are uncompromised by the valve; 
• Have a long-term shelf life without changes in properties and sterility; 
• Be available in all sizes with design features adaptable to individual patients 
requirements; and 
• Be reasonable priced. 
There is currently no prosthetic heart valve that meets all of the criteria listed above. 
With respect to bioprosthetic tissue valves immunogenicity remains a key 
determinant of their potential for success or failure and our exploration aimed at 
modifying and/or masking residual antigens capable of eliciting a host response is 
justified in the quest to prolong the life of a bioprosthetic heart valve. 
82.1. Mechanical heart valves 
Mechanical heart valves are constructed of rigid supporting materials and mobile 
components using only inert, biocompatible materials such as pyrolitic carbon, 
polyester (Dacron)-covered polymers, or meta Is 26. All mechanical valves have a 
similar basic structure with three essential components: (1) the occluder, (2) the 
housing and (3) the sewing ring. The occluder is one or more moveable part, which 
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may be a Dall , a diSC, or a hinged leaflel The occluder I~s til the tlOUSlllg whICh help 
lhe IXcluder 10 move by gUiding and reslnCling liS mo~emellt The fabrlc-sewlIlg cul1 
IS attached 10 the houSing, 10 allow Implamalion 01 the device'" Blood Pfessure 
dll1erences wlthlll the chambers of the heart enaD~ these mechallical valves 10 
function properly 
There are Ihree general deSigns for mechanICal valves, Dall-rn·cage valves. 1 1 ~lng· 
dl!;C valves and b l leaf~t ~al~es" ". lO Currently the most commonly used 
mechanical valves are the bl leallet valves Mechanical valve compllCaltons IflClude 
design or matenClI failure inlecllonS, and ttssue overgrowth Siructural failure of 
mechClntcal valves IS almost none~ lstenl and they can be upectect to perform 
properly for at least 20 years'" Imperfect blood now through some of these devlc.s 
can create non-physlOlo\lICClI p;;ttterns that may Induce ttle ICH'lTI<ItlOn of blood Clots 
Furthermore the surfaces e~posed directly to blood flow are not entirely non-
thrombogeniC Clnd mechanical valves are plone 10 thrombonlO Thus PClttenlS are 
require(! 10 take anticoagulatIOn medIcatIOns fCH' the rest of then IIvesl2 
A , 
Figure B-3 The generClI deSJgns 01 mechClnlcal valves A) ball-In-cage valves. B) 
IItI,ng-dlsc valve <II'ld C) blleaflet valvl!5 
AntICoagulatIon treatment IS ClssOl;IClted wttll bleeding complications" The 
COI'lsequence III first world countnes IS overregulated whereas in developmg or third 
world counTnes subopnmill 3Ill>COClguiatulg IS the norm often result,,,\! III fatal acute 
thromboembolIC events Pallen,s WIth contraindication lor antlcoagulatlQf1 and 'n 
developing countries with limited access to healthcare facilities should therefore 
ideally have a bioprosthetic heart valve implanted, although currently the trend is 
towards the use of mechanical valves in these countries due to a resistance by 
surgeons who are fearful of having to perform complicated and high risk redo valve 
replacements at a later stage. Mechanical valves are not recommended for pregnant 
women, or women considering pregnancy, because Warfarin (anticoagulation 
treatment) is associated with embryopathy (a developmental disorder in an embryo), 
spontaneous abortions, stillbirths, and less commonly, central nervous system 
defects and fetal bleeding with exposure beyond the first trimeste~1. 
B2.2. Biological heart valves 
Biological heart valves may be divided into two groups. The one group are tissue 
heart valves prepared from human tissue specifically homografts or autografts. The 
second group are bioprosthetic heart valves prepared from chemically treated animal 
tissue such as porCine aortic valve tissue or bovine pericardial sheets. Currently, 
45% of heart valve replacements are bioprosthetic valves25. Bioprosthetic heart 
valves are the prosthesis of choice in elderly patients since anticoagulation is 
avoided14, 32-35_ These valves are contraindicated in children and adolescents, 
however. as they produce severe short-term calcification36-38 with acute 
hemodynamic deterioration necessitating urgent valve replacemenf3· 39, 40_ 
Homografts are a popular choice but its use is restricted to less than 5% of cases 
because of their limited availability. 
B2.2.A Autografts (Ross procedure) 
Autografts were first used in 196r1• The Ross procedure is a procedure for patients 
requiring aortic valve replacement42-45, In the Ross procedure41 the diseased aortic 
valve is replaced by the patient's own pulmonary valve (autograft). The patienfs 
pulmonary valve is replaced by an aortic homograft. This procedure is attractive for 
children. athletes and woman of childbearing age because it eliminates the use of 
anticoagulation and has the potential for somatic growth46. 
The major concem is the complexity of insertion technique and the long-term 
consequence of trading one diseased valve for the possibility of two diseased valves. 
There is a risk of dilation and consequently insufficiency in the pulmonary autograft43, 
47 and is the leading cause of late reoperation. Homograft stenosis is the primary 
reason for reoperation of the homograft valve42. 48, 49, Structural valve degeneration 
and calcification do not appear to be common complications with pulmonary 
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autografts. Freedom from reoperation 20 years after the Ross procedure can be 
expected to be 75% for the autograft and 80% for the homograft49, 50. Autografts 
have excellent durability after implantation, but are not readily available for all 
patients8. 
B2.2. B Homografts 
Homografts were first used in 196217 and involve valves harvested from human 
cadavers. In 1962 Ross performed the first homograft replacement of the aortic 
valve using a freeze-dried valve from a cadaver17• Preservation of valves harvested 
from cadavers to increase storage times improved availability and access to 
homograft valves. The standard storage technique for homograft valves is 
cryopreservation using cryoprotectants and storage in liquid nitrogen vapour at -
180°C. Cryopreserved homograft valves have morphologically intact tissue structure 
at the time of implantation51 and are superior to fresh homograft valves52-54 . 
Cryopreservation allows storage of homograft heart valves for years while 
maintaining graft viability53. 
Cryopreserved homograft valves nevertheless have been shown to elicit a host 
immune response55-59. These valves have decreased durability in younger children, 
which has been attributed to an accelerated immune response-mediated valve 
failure58, 60. The graft contains viable interstitial cells61 , 62 and endothelial cells51, 63 
that may contribute to the immune response64. Specifically the viable cells present in 
cryopreserved homograft human valves are capable of expressing human leukocyte 
antigen class I and II antigens and induce alloantibodies60, 65, which could damage 
transplanted tissue and contribute to early degradation of homograft function 59, 60. In 
homograft implants blood group incompatibility between recipient and donor may 
also playa role in homograft dysfunction and fibrocalcification, particularly in very 
young patients (3 years old or younger)51, 55, 66. Cryopreserved homograft valves 
have viable cells at the time of implantation, but experimental studies showed early 
cell death from metabolic depletion67,66. Currently, decellularised homograft valves 
are also used and clinical studies indicate a reduced immune response and the 
potential to repopulate with host cells69. 
B2.2.C Bioprosthetic heart valves 
Porcine aortic valves were first used in 196518. These valves are composed of 
animal tissues that have been chemically treated to improve their biocompatibility. 
Cross-species implantation of untreated animal tissues is prone to severe immune 
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rejection and rapid tissue degeneration and resorption, For this reason, bioprosthetic 
heart valve tissues are treated with glutaraldehyde, which covalently cross-links 
protein70 to suppress immunogenicity71. 72 and stabilise the tissue against proteolytic 
degradation once implanted73• 74, Porcine bioprostheses for valve replacement was 
first used in 196518, In the 1970s, bovine pericardial valve constructs were also 
used75, Currently, the predominantly used bioprosthetic valves are made from 
glutaraldehyde treated porcine aortic valve tissue or bovine pericardia I tissue, 
designed to imitate the flow and material properties of the human heart valve. 
Bioprosthetic valves have central flow, good hemodynamics and good thrombo-
resistant surfaces. Glutaraldehyde fixation is often believed to be directly 
responsible for calcification of bioprosthesis76, the main reason for structural valve 
deterioration77, The xenograft material is antigeniC and must nevertheless be cross-
linked to prevent acute rejection, As a result glutaraldehyde is used at lower 
concentrations (0.2% - 0.6%) to reduce the risk of calcification, with minimal regard 
for the risk of inflammation and immune responses, 
B2.2.C(1) Stented versus non-stented valves 
The three main designs of bioprosthetic valves are stented porcine valves, stented 
pericardial valves and non-stented porcine valves25. Stented valves are made from 
either glutaraldehyde treated porcine aortic valve tissue or glutaraldehyde treated flat 
sheets of bovine pericardial tissue mounted on a stent made of metal or plastic and 
covered with synthetiC fabric25. The stent facilitates handling, insertion and 
attachment of the prosthesis to the recipient aortic root, but it adds a bulky, 
non biological component to the bioprostheses. The non-stented porcine valves 
overcame this problem, using whole porcine aortic root fixed in glutaraldehyde, with 
minimal or no fabric cover78, Although promiSing improved hemodynamics. these 
valves are more difficult to implant and are ignored by the majority of surgeons, 
Second generation pericardia I valve deSigns have better hemodynamics over stented 
porcine valves and similar hemodynamics to non-stented porcine valves. The 
fundamental advantage of stentless valves over stented valves is greater orifice 
area. These have very low to zero residual gradient19 and excellent 
hemodynamics79. However, non-stented valves have similar structural valve 
deterioration rates and may fail at the same rate as stented valves80. 
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B2.2.C(2) Failure modes of bioprosthetic valves 
The first generation porcine aortic valves suffered from structural valve degeneration 
due to calcification and bovine pericardial valves had design-related problems with 
shorter lifetimes due to leaflet tears than porcine aortic valves 81,82. These valves 
were fixed at high-pressure giving very stiff, noncompliant leaflet material and cause 
flexure fatigue-related valve leaflet damage83 . I n the 1980s, high-pressure fixation 
was abandoned in favour of low-pressure fixation and anti-mineralization treatments 
were applied to improve the durability of second-generation valves84• Second 
generation bioprosthetic valves though have similar structural valve deterioration 
rates32. 
The limitation of bioprosthetic heart valves is durability in the long-term. The leading 
cause of bioprosthetic heart valve dysfunction is structural valve deterioration, which 
begins to increase 5 to 6 years after implantation33, 39. 
83. Structural valve deterioration 
The major two determinants of bioprosthetic heart valve structural degeneration that 
receive the most attention in literature are dystrophic calcification and mechanical 
damage with minimal emphasis on inflammatory and immune processes, which only 
now are being recognized. 
After implantation bioprosthetic heart valves undergo a complex, time-dependant 
process of structural changes, resulting in the dysfunction of the valve. Repeat 
surgery for replacement of bioprosthetic heart valves is a relatively common event. 
Clinical follow-ups indicate that more than 50% of patients with artificial heart valve 
implants develop complications within 10 years 12. The major cause of repeat surgery 
for bioprosthetic heart valves is structural valve deterioration, which refers to 
dysfunction of the valve resulting from any intrinsic degenerative change causing 
stenosis or regurgitation33, 39,85. 
Bioprosthetic heart valve degeneration is a complex process. In clinical studies of 
the failure of bioprosthetic heart valves, the term structural valve deterioration is used 
without clear1y classifying the cause of failure as either calcification, primary tearing, 
pannus outgrowth, leaflet dehiscence or a combination of causes. Tearing of leaflets 
was due to calcification, which leads to higher stress and secondary collagen fibre 
damage and leaflet tearing. Vesely et al86 studied this hypothesis and found leaflet 
tears develop independent of calcification as a result of mechanical damage. 
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Bioprosthetic heart valves constructed from porcine aortic valves or bovine 
pericardial sheets, which are obtained from the abattoir, begin to degrade 
immediately. Major degenerative changes already occur during tissue preparation of 
these heart valves. The cells lose their viability, the endothelium is largely denuded 
and extracellular matrix components are modifiect'. The material is cross-linked 
primarily to mask antigenic properties87 and secondly to stabilise the tissue, resulting 
in a nonviable material that at best maintains the original structural and some degree 
of mechanical integrity of the tissue. Biological integrity is however, lost. 
83.1. First versus second generation valves 
First-generation bioprosthetic heart valves were valves from porcine aortic tissue and 
bovine pericardium tissue fixed with glutaraldehyde at high pressure without any anti-
mineralization treatment. Calcification was the major cause of failure for first-
generation porcine bioprosthetic heart valves88• Primary leaflet tears were the major 
problem for first-generation bovine pericardium bioprosthetic heart valves89• 
Porcine and pericardial tissue valve designs were revised and second-generation 
valves were fixed in glutaraldehyde at low pressure and treated with anti-
mineralization agents. They have comparable long-term freedom from 
thromboembolism, endocarditis, and nonstructural valve complications90. 
The ten year study of Butany et al91 found that structural valve degeneration 
neverthless still remains the major problem. Prosthetic valves explanted after failure 
showed high rates of stent deformation, calcification, and pannus overgrowth. 
Analysis of explanted mechanical and bioprosthetic valves revealed overall causes of 
failure which included perivalvular leaks, thrombosis, host tissue overgrowth, 
degeneration or mechanical failure, and susceptibility to infections92. Complications 
related to thrombogenicity are the major problems of mechanical valves, whereas 
tissue-derived valves are mainly affected by the degeneration and calcification of the 
tissue components. 
83.2. Calcification of bioprosthetic heart valves 
The failure of bioprosthetic heart valves is mainly due to tissue valve calcification8, 88, 
90,91,93-96. Calcium deposits increase stiffness, weaken the tissue, reduce the pliability 
of the leaflets, tearing, and results in stenosis or insufficiency, or both. The 
mechanisms of calcification and the factors that induce the calcium hyroxyapatite 
crystal formation are not fully understood and many hypotheses are proposed. The 
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cross-linking process and the presence of foreign proteins and cells appear to playa 
key role in calcification of tissue heart valves. 
83.2.A Factors that influence bioprosthetic heart valve calcification 
Many independent factors determine calcification and can be summarised as 1) 
implant composition, 2) chemical treatment, 3) mechanical factors, and 4) host 
factors. 
B3.2.A(1) Implant composition 
The main tissue types used for bioprosthetic heart valves are from bovine 
pericardium and porcine aortic valves. The valve leaflets and aortic walls are used to 
construct either a stentless valve (part of the aortic wall tissue with the leaflets and a 
small fabric covering) or a stented valve (valve mounted on a stent with fabric sewing 
ring covering the valve orifice at the base). Bioprosthetic tissue consists of cells 
embedded in an extracellular matrix composed mainly of varying proportions of 
collagen, elastin and glycosaminoglycans (GAGs) (see table 1). Pericardial tissue is 
mainly composed of collagen97• The major difference between leaflets and aortic 
wall tissue is the composition of the extracellular matrix components. Collagen type I 
is a major component of leaflets extracellular matrix whereas elastin is the major 
extracellular matrix component of post-sinotubular junction aortic wa1l98• 
Examination of explanted bioprostheses indicates that calcification is associated with 
mitochondria, membrane fragments and cell debris of all glutaraldehyde fixed tissues 
used for bioprosthetic heart valves99. 100. However, collagen calcifies readily in 
leaflets and pericardium, and elastin calcifies independently in the aortic walls 
irrespective of glutaraldehyde treatment97, 98. Thus, cells or cellular materials are not 
solely responsible for calcification of bioprosthetic tissue. Collagen and elastin can 
serve as nucleation sites for calcium phosphate minerals, independent from cellular 
components8• 96• Collagen and elastin calcification is poony understood. Elastin is 
hydrophobic and may adsorb cellular material. 
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B3.2.A.1(i) Cellular components 
Cells are the major sites of initiation of mineral deposits99-102. Glutaraldehyde 
treatment does not remove nonviable connective tissue cells. Although the 
mechanism of calcification of the cells is yet to be fully understood, one hypothesis 
for the mechanism of calcification of bioprosthetic tissue is that nonviable cells lack 
the ability to maintain local calcium concentration gradients across the cell 
membrane. In living cells calcium uptake occurs through gradient dependent passive 
channels. Calcium is released from the cell via Ca2+ -ATPase pumps to maintain 
calcium homeostasis. There is a 10,OOO-fold calcium ion concentration gradient 
across the plasma membrane with intracellular calcium lower than the calcium rich 
extracellular fluid103-105. Thus, calcium is passively transported into the cell and 
actively pumped out with the ATP-pump. This regulation mechanism is disrupted in 
bioprosthetic tissue where calcium ions flood nonviable energy-depleted cells with 
disrupted membranes 102, 106. 
Plasma membranes and membrane-bound organelles, such as mitochondria, are 
rich in phospholipids and provide phosphorous for apatite formation96• The cell 
membrane has trans-membrane proteins, imbedded in a double-layer lipid 
membrane, with acidic phospholipids exposed inside the cells. There is an 
electrostatic attraction between the acid phospholipids of the connective tissue and 
calcium107. Calcium floods the cell and nucleation of calcium-phosphate crystals 
occurs at the phospholipid-rich membranes and calcium-binding proteins8 . The 
inorganic phosphate ions combine with the calcium ions and the continuous influx of 
calcium ions lead to the formation of hydroxyapatite97. 
Cunanan et al107 found a statistically Significant direct correlation between 
phospholipid levels and calcification; lower phospholipid levels being associated with 
lower calcium levels. The cellular role in calcification is supported by the prevention 
of calcification by lipid extraction from biological tissue, especially of phospholipids, 
which are present in cell membranes 100. 
Native human heart valves are covered by a monolayer of endothelial cells, which 
act as an effective barrier between the blood and the tissue. During the fixation 
process the bioprosthetic heart valves lose this endothelial barrier101. 108. Structural 
alterations on the surface of leaflets from explanted porcine bioprosthetic valves 
involved loss of endothelial cells, exposure of large areas of basement membrane 
material, fibrin depostion and insudation, presence of activated Ie ucocytes , adherent 
22 
platelet aggregates and focal accumulation of crystalline deposits108• A confluent 
endothelial lining may suppress plasma insudation, extrinsic calcification of mural 
microthrombi and immune responses in the underlying tissue. There is however little 
or no spontaneous, natural endothelialisation of bioprosthetic heart valves through 
outgrowth of host endothelial cells 109. Unless the tissue is quiescent with regard to 
an inflammatory response, endothelial seeding or overgrowth is inefficient at avoiding 
an, often severe, inflammatory response at the tissue interface. 
B3.2.A.1(ii) Collagen 
Collagen fibres are a major constituent of leaflet extracellular matrix and pericardium 
(see table 1). They provide the architectural framework and mechanical 
reinforcement needed for function in a bioprosthetic heart valve97• A collagen 
molecule consists of three polypeptide chains arranged in a triple helix configuration 
ending in non-helical carboxyl and amino terminals, one at each end. These non-
helical ends are believed to contribute to most of the antigenic properties of collagen. 
Calcification patterns, observed in both in vitro and ex planted valve tissue, show that 
collagen plays a role in valve calcification. Firstly, calcification was seen to align 
longitudinally along collagen fibre bundles, secondly, calcification occurs 
perpendicular to the fibre bundles in banded patterns and thirdly, large, dense focal 
deposits damage the underlying collagen structure 110. Fixation of the tissue changes 
the morphology and the charges on the collagen molecules111 which might facilitate 
complex formation with calcium ions. Collagen is present in the matrices of all three 
major skeletal tissue calcification structures: bone, cartilage and dentin112. 
Purified type I collagen sponges prepared with increasing concentrations of 
glutaraldehyde implanted subcutaneously for 21 days in rats calcified, but the degree 
of calcification did not correlate with the extent of assumed cross-linking. However, 
purified type I collagen gels resorbed without evidence of calcification 113. The 
investigators concluded that cross-linking with glutaraldehyde promotes the 
calcification of collagen sponge implants made of pure collagen. Vincentelli et al114 
suggested that collagen type I sponges resorbed without evidence of calcification 
may demonstrate that the immunologic rejection of the collagen sponge did not leave 
time for calcification to occur. 
Simonescu et al115 demonstrated that collagen and elastin degrading enzymes are 
active in glutaraldehyde-fixed aortic leaflets and wall tissues and that these 
proteases are able to degrade glutaraldehyde-fixed collagen and elastin. 
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Progressive collagen breaks, independent of calcification-, also contribute to the 
limited durability of bioprosthetic valves. 
B3.2.A.1(iii) Elastin 
Elastin, a structural protein of the extracellular matrix, is a major component of elastic 
fibres in connective tissue and in contrast with leaflets, the major component of aortic 
wall tissue (see table 1). Aortic wall calcification seems to differ from bioprosthetic 
heart valve leaflet calcification. Contrary to leaflets, elastin appears to be the major 
site of extracellular calcific deposits in aortic wall tissue116. Elastin is highly 
hydrophobic, insoluble, is rich in non-polar amino acids and has very few free lysine 
groups to react with glutaraldehyde117. The lack of reactivity of glutaraldehyde with 
elastin suggests that elastin is not protected against the activity of degradative 
enzymes, such as matrix metalloproteinases (MMPs)118. The elastin-associated 
microfibrils are disrupted during the preparation of bioprosthetic aortic wall tissue 
leaving the elastin core exposed9• Elastin degradation products could possibly elicit 
immune responses and trigger unwanted reactions in host cells such as protease 
release119, 120. Degradation and fragmentation of elastin fibres appears to cause 
increased elastin-orientated calcification98• Inhibition of matrix metalloproteinase 
activity Significantly inhibits elastin calcification when implanted subcutaneously in 
rats 121 lee et a1122 found MMP-mediated (MMP-9 and MMP-2) elastin degradation is 
involved in initiation and progreSSion of pure porcine aortic elastin calcification. 
Thus, elastin degradation may be the primary step in pathologic elastin calcification. 
Vyavahare et al117 used pure elastin to study elastin calcification independent from 
the effects of structural components of the aortic wall (cells, phospholipids, 
glycosaminoglycans, intrinsic enzymes and other extracellular matrix proteins). They 
demonstrated that purified elastin calcifies in a rat subdermal model independent of 
glutaraldehyde. Thus, glutaraldehyde treatment is not a prerequisite for aortic wall 
calcification. 
B3.2.A.1(iv) Glycosaminoglycans and proteoglycans 
Glycosaminoglycans are long, hydrophilic, anionic, unbranched polymeric molecules 
consisting of disaccharides4, present in valves and pericardium tissue123. They bind 
to a core protein as large polymers to form proteoglycans. They are distributed in the 
extracellular matrix of leaflets (particularly within the spongiosa) and aortic wall 
tissues, and are also associated with the surfaces of collagen and elastic fibres9. 
Proteoglycans reside in empty areas created in collagen fibres and it has been 
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suggested that they protect collagen from calcification. Proteoglycans and 
glycosaminoglycans reduce calcification by chelating calcium ions 124, thereby 
preventing hydroxyapatite nucleation and thus effective inhibitors of mineralization 123-
125. Glycosaminoglycans are capable of absorbing water and swell to form a gel to 
resist compression forces and play an important role in maintaining proper 
mechanical functions within bioprosthetic heart valves5-7, 10. Glycosaminoglycans 
lack amine groups necessary for cross-linking by glutaraldehyde and are lost in vitro 
during bioprosthetic heart valve preparation, fixation and storage as well as when 
implanted'" 9, 10, suggesting insufficient stabilisation by glutaraldehyde. Matrix 
metalloproteases 115 and glycosaminoglycans-degrading enzymes 126 can degrade 
proteoglycans and may contribute to bioprosthetic heart valve degeneration. 
Lovecamp et al4 did a comprehensive study of glycosaminoglycans' role in porcine 
bioprosthetic heart valves. They found the loss of glycosaminoglycans may impact 
on the mechanical durability of bioprosthetic heart valves, but plays a minor role in 
the calcification of valves implanted in the rat subdermal model. 
83.2.A.1 (v) Fibronectin 
Fibronectin (Fn) is a large extracellular glycoprotein found in body fluids (mostly 
plasma), soft connective tissue matrices, and most basement membranes. There 
are at least two types of Fn termed plasma and cellular Fn. They are structurally and 
functionally very similar, but not identical. The two forms are indistinguishable in the 
biological activities in assays but in contrast the effects of these molecules on cell 
morphology are sometimes substantially different 127. As an insoluble multimer, it is a 
key component of the extracellular matrix 128. Fn is usually formed as a dimer, 
conSisting of similar but not identical chains, and each polypeptide chain is 
approcimately 250 kDa in size. A pair of disulfide bonds joins the carboxy-terminal 
end of the chains 129. Proteases cleave Fn in regions to generate separate, 
structured domains of the molecule containing specific binding sites for ligands such 
as collagen, heparin sulfate, fibrin as well as a cell binding domain (see Figure 8-6, 
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B3.2.A.l (vi) Non..coUagenous components 
Non·collageneous proterns 01 the e~t racellullilr matn~ such as osleoponton 
osteocalcln and osteonectln are normally present and e~pressed lilt specific stages of 
bone development and regu late calCIfication in bone matnx,3Q Thus non· 
co llageneous components pililY Hll)ortanl roles ,n calCIum nameostas,s w~hll' the 
extraceHular mlillriK Non·collagenous bone protems. osteopontln osteoc;alon ilnd 
osteone<;hn and extracellular bone maln~ prole Ins have been reported in 
bloproslhehc hssue calct/,catlon"T'" The exact funct IOns 01 these prOle,"s are yet 
unkJ'lown. If thE!)' are iii cause Q( a consequence of the caict/,caloon process These 
proteins may play a s'llnllieant role In the regulation of calCIfication It IS 
hypotheSised thaI oSleopOntm regulates calclfiCiltlOn In blOproslhetlC hSSIJ'e by 
b,ndlng 10 hydroxyapaute and lhat " physlCall)' mhlblts cryslalgrowth'" OSleocalc,n 
and osteonect61 may serve 10 reglllale cryslal growtn and monel'al rE!$Orpt'on'l:i 
Macrophages and smooth musde cells synthesIZe non·cogagenous malnx 
proteins'" Snvalsa et ai'" fOiJl'!d osteopontln. oSleocalcm. and osteonectm prOle," 
adjacenllo and w~hln regIOns of mlflerahzatlon of b!oprosthetoc valves Macrophage 
celllflfiltrat,on was also observed surrounding calcified areas 
" 
83.2.A(2) Chemical treatment 
Chemical treatments that stabilise bioprosthetic heart valve tissue influence the 
degrees of degradation and calcification, Glutaraldehyde treatment is commercially 
used to create chemically stable cross-links in collagen fibres of bioprosthetic tissue 
to improve durability. Glutaraldehyde treated materials calcify to a large extent106, 
which might be due to the cross-linking process. Glutaraldehyde fixation of 
xenografts can lead to several biochemical and structural determinants that plays a 
detrimental role in bioprosthetic heart valve tissue calcification 136, 137, The role of 
glutaraldehyde in calcification is not clearly defined. 
In normal leaflets, valvular interstitial cells and resident macrophages actively 
partiCipate in maintaining tissue architecture via constant remodelling97• 
Glutaraldehyde treatment devitalises tissues, cross-links nonviable cells but does not 
remove them leaving cell debris that can serve as nucleation sites for calcification8, 96, 
101, 138, Kim et al139 showed that glutaraldehyde fixation leads to influx of Ca2+ into 
cells followed by apatite nucleation. Tissue injury during harvesting of the valves and 
a delay in glutaraldehyde fixation was shown to intensify calcification of bioprosthetic 
heart valves in the subcutaneous rat model140, 141, 
Incomplete glutaraldehyde binding to tissue proteins, loosely bound glutaraldehyde, 
or free aldehyde groups result in cytotoxic reactive aldehyde group residuals and 
polymeric glutaraldehyde cross-links that can depolymerise142. Depolymerization of 
polymeric glutaraldehyde cross-links has been reported, which releases monomeric 
and highly cytotoxic glutaraldehyde into the recipient142. The free aldehyde groups 
seem to be involved in bioprosthetic heart valve calcificiation94, 97, Glutaraldehyde 
treatment changes the morphology and charges on the collagen moleCUles 111, which 
may be responsible for calcification. Neutralising (chemical treatment with amino 
compounds to reduce residual glutaraldehyde released from fIXed tissue) and excess 
rinsing after glutaraldehyde fIXation minimise cytotoxicity and reduce calcification 
potential143, Higher glutaraldehyde concentrations (3%) reduces tissue calcification 
in both the circulatory sheep model144 and subcutaneous models141 . Better cross-
linking improves ultrastructural tissue preservation 145, reduces macrophage 
activation146, and suppresses the immune response147. 
Glycosaminoglycans are natural inhibitors of calcification4 but fail to be stabilised 
within the glutaraldehyde cross-linked heart valve tissue and as a result are lost from 
bioprosthetic heart valves4, 9,10, Thus, fixation of bioprosthetic tissue alters structural 
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and biochemical characteristics of the tissue significantly. These changes playa 
direct or indirect role in calcification of the bioprosthetic heart valve. 
83.2.A(3) Host-related factors 
The role of the host in calcification is unclear. Certainly, the age of the recipient does 
play a role in the time period for structural valve deterioration. Bioprosthetic heart 
valves calcify at an accelerated rate in young children38-38, 148 and growing adults with 
active immune responses and rapid growth14. 39. The small sized valves used in 
children result in increased pressure gradients and stress on the leaflets, which may 
enhance early tissue fatigue. Calcium turnover is high in children who maintain a 
positive calcium balance149. Patients with abnormal calcium metabolism such as 
patients with renal failure and patients with bone tumours have soft tissue 
calcification97, 150. Accelerated degeneration and calcification of bioprosthetic valves 
in these patients with a high calcium turnover suggests that calcium metabolism148 
may playa role in bioprosthetic heart valve calcification. 
The donor and reCipient species influences the onset and degree of calcification. 
Carpentier et al151 found pig a favourable donor of bioprosthetic tissue. The donor 
species order of calcification was the highest in bovine, then sheep and lowest in pig 
when implanted subcutaneously in rats. Subcutaneous implantation of 
glutaraldehyde-treated porcine and bovine leaflets showed the highest ratio of 
calcification in rabbits compared to rats, with no calcification in cow and hen. Even 
the different strains of animals can affect the calcification response. The highly 
inbred immune-tolerant Fischer-344 rat calcifies bioprosthetic tissue much less than 
other strains such as Long-Evans, Wistar and Sprague-Dowley rats 106. 
The host immune response to bioprosthetic tissue remains highly debated in the 
literature. Untreated vascularised xenograft tissue triggers a hyperacute rejection 
within minutes of implantation. The chemical cross-linking of bioprosthetic heart 
valve tissue dramatically masks the tissue's antigenicity but standard commercial 
glutaraldehyde fixation does not eliminate the immune response152-154 and 
bioprosthetic heart valves continue to fail albeit over many years rather than days. 
The mild inflammatory response to the tissue nevertheless results in slow 
degradation of the tissue. Implantation of bioprosthetic heart valves certainly has 
been shown to induce a foreign body type response92• 107. 
Eariy clinical studies suggested the host's immune response to bioprosthetic heart 
valves might also contribute to calcific degeneration155. 156. Investigators found 
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infiltration of plasma cells, histiocytes and an immunoglobulin response in failed 
bioprosthetic heart valves in children 157. In the 19805, Levy's group investigated the 
possible contribution of the immune response. In a study which involved 
subcutaneously implanted Millipore diffusion chambers containing glutaraldehyde-
treated porcine valve leaflets they suggested that normal T-Iymphocyte function nor 
"immunologic processes" contributed to the process of bioprosthetic heart valve 
calcification 158 since the Millipore diffusion chambers, which allow extracellular fluid 
infiltration but prevent host cell migration, did not affect calcium accumulation, 
whether in the presence or absence of host cells. Indeed, the morphologic 
appearance of calcium in glutaraldehyde-treated tissue in normal and nude mice (T-
lymphocyte deficient) were identical 21 days after implantation. This suggested a 
passive, rather than cell-mediated calcification process. However, they failed to 
address the role of a T-Iymphocyte independent immune response. Many 
investigators believe this evidence suggests that neither specific nor non-specific 
immune responses playa role in bioprosthetic heart valve degeneration and that no 
contributory immunologic basis has been demonstrated for bioprosthetic valve 
calcification or failure. Schoen and Levy8 suggest in their review of tissue heart valve 
calcification that circulating antibodies to valve tissue detected in experimental and 
clinical studies may be a secondary response to valve damage rather than a cause 
of failure. Similarly one could argue that macrophage infiltration is a consequence of 
collagen degeneration rather than its cause, although studies have demonstrated 
phagocytosis of intact collagen by macro phages. Liao et al159 compared autograft, 
allograft and xenograft tissue implanted in the subcutaneous Sprague-Dawley rat 
model. Tissue was either untreated or treated with 0.625% glutaraldehyde for 
different time periods. Calcification increased with fixation time in treated groups 
whereas untreated tissue did not calcify. They concluded that calcification was not 
related to the antigenicity of the implants, but the glutaraldehyde treatment. 
Magilligan et al160 found no second-set rejection in patients with bioprosthetic heart 
valves replaced by a second bioprostheses. Some investigators suggested that the 
immune mechanisms contributing to bioprosthetic heart valve failure may not lead to 
dramatic immediate rejection, but may playa significant role in the degeneration of 
the valve over time. Nimni et al153 showed commercial fixation with glutaraldehyde 
only achieves 59% reduction in antigenicity as opposed to 92% reduction through 
enhanced fixation using diamine bridges. 
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The potential role of inflammatory and immune processes is still unclear but a 
growing number of researchers provided evidence for immune-mediated 
bioprosthetic heart valve degeneration: 
• The presence of circulating graft-specific antibodies in clinical and 
experimental studies73, 94,154,157 
• Experimental animals can be sensitized to both fresh and cross-linked 
bioprosthetic valves tissues 152, 154, 161 
• Failed bioprosthetic heart valves have mononuclear inflammation with 
macrophages identified as the main invading and collagen-degrading 
inflammatory ceU101, 162. 
• Eishi et a1163 observed a decrease in calcific degeneration of bioprosthetic 
heart valve patients with steroid therapy for aortitis (inflammation of the 
aorta). 
• Oahm et al152 indicated that glutaraldehyde-tanned bovine pericardium elicit 
both a cellular and humoral immune response. 
• Vincentelli et al114 found a possible link between inflammation and 
bioprosthetic heart valve failure. They compared 0.6% glutaraldehyde treated 
autologous and heterologous pericardial samples implanted subcutaneously 
in sheep. The heterologous group calcified 35 times more than the 
autologous grouP. suggesting that an immune response may be responsible 
for the changes and not the glutaraldehyde treatment. 
• Human and Zilla 161 directly linked bioprosthetic tissue specific antibodies and 
calcification. They incubated glutaraldehyde treated porcine aortic wall in 
serum containing high levels of graft-specific antibodies before subcutaneous 
implantation in rabbits. The tissue calcified three times more than tissue 
incubated in pre-immune serum. 
83.2.A(4) Mechanical stress 
Mechanical stresses in the heart contribute to calcification of bioprosthetic heart 
valves164-166. The right side of the heart supplies blood only to the lungs. while the 
left side of the heart must supply blood to the rest of the body. Therefore. the left 
side develops pressure ten times higher than in the right side of the heart. 
Bioprosthetic heart valves calcify less after being implanted in the left (aortic and 
mitral valve) side of the heart as compared to the right side (pulmonary and trileaflet 
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valve)97. Greater incidence of valve degeneration for mitral valves is likely due to a 
higher closing pressure33• 
Leaflet calcification appears to be concentrated in areas of high stress. There is a 
relation between the distribution of mechanical stress in the leaflet and calcification. 
Distribution of mechanical stresses in the leaflet is highest near the commissures, 
then at the free margin and lowest at the base of the leaflet. Calcification is most 
frequently observed near the commissures, less in the body of the leaflet and free 
margin, and least at the base of the leaflet167. 
Intrinsic and extrinsic mineralization is observed at sites of intense mechanical 
deformation generated by motion, such as the points of flexion in heart valves95. 
Pericardial bioprostheses calcify where the highest stress occurs, particular in the 
areas of flexion of the leaflets. Mechanical stress damages the structural integrity of 
the leaflet tissue166. 
Modification of design and tissue properties to duplicate those of natural aortic valves 
may improve the durability of bioprosthetic valves. 
B3.2.B Prevention of calcification 
Calcification is the primary reason for bioprosthetic heart valve failure. Therefore 
bioprosthetic heart valve treatments are directed at prevention of calcification. The 
treatments target different factors involved in calcification. Combinations of the 
approaches may be more effective in preventing calcification. Nimni et al106 
suggested the ideal treatment should include removal of non-covalently bound 
glutaraldehyde, neutralisation of free aldehyde residues, removal of lipids and non-
collagenous proteins and the inclusion of calcium phosphate inhibitors. 
Glutaraldehyde has been branded the villain 156 and most strategies target 
glutaraldehyde by incorrectly decreasing concentrations used rather than avoiding 
the problem of slowly leaching glutaraldehyde monomers due to labile bonds through 
appropriated detoxification. 
83.2.8(1) Inhibitors of calcium phosphate mineral formation 
B3.2.B.1(i) Biphosphonates 
Biphosphonates act as a crystal'poison,106 by binding to developing hydroxyapatite 
crystals, and thereby preventing further crystal growth 166, and as a result inhibiting 
calcification. Biphosphonates can be administered systemically or locally. Systemic 
administering has been associated with Significant adverse effects 169. Rats receiving 
subcutaneous injections daily showed severe somatic growth retardation and 
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elevation of the serum calcium levels. Locally systematic delivery of biphosphonates 
using controlled-release delivery systems or pre-treatment of the leaflets with 
biphosphonates prevented these effects and animals had normal somatic growth and 
serum calcium levels 170. Biphosphonates significantly inhibit bioprosthetic aortic wall 
calcification 116 and calcification of bioprosthetic leaflets implanted subcutaneously in 
young rats 170. 
B3.2.B.1(ii) Trivalent metal ions (AI3+ or Fe3+) 
Trivalent metal ions can bind at phosphorous-rich loci of devitalised cells 171, 172. The 
A13+ or Fe3+ ions inhibited calcification by forming a phosphate complex, thereby 
preventing calcium phosphate formation or arresting crystal growth 173. These ions 
also inhibit alkaline phosphatase171 , 173, an important enzyme involved in bone 
formation activity and this may be related to their ability to prevent initiation of 
calcification. Aluminium ions bind irreversibly to elastin, inducing permanent 
alteration in the elastin structure such that it resists calcification117. Aluminium ions 
also partially stabilise pure elastin against matrix metalloproteinase-mediated 
elastolysis, and protect it from degeneration and calcification when tested in animal 
models 174. Fe3+ and AI3+ significantly inhibit bioprosthetic heart valve leaflet as well 
as aortic wall calcification116, 171, 172, 175. Calcification of purified elastin in a rat 
subdermal implantation model is also inhibited by aluminium chloride pre-
treatment117. 
83.2.8(2) Removal or modification of calcifiable material 
B3.2.B.2(i) Surfactants 
Detergents, such as sodium dodecyl sulfate (SDS)176, Tween 80177, and Triton X-
10086 are used to inhibit mineralization in bioprosthetic heart valves. Detergents 
reduce calcification by removing acidic phospholipids, which result in suppression of 
the initial cell membrane oriented calcification 176. The detergent pre-treatment could 
also be responsible for extracting proteins, removing cell debris or interfering with 
adsorption of proteins, thereby reducing the capacity to adsorb non-collagenous 
bone proteins103. Detergents reduce calcification in subcutaneous implantation 
models, but the results are not as favourable in circulatory models 177, 178. SDS is not 
an efficient anti-mineralization treatment177. 
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B3.2.B.2(ii) Ethanol 
Ethanol extracts phospholipids and cholesterol from glutaraldehyde fixed leaflets and 
induces permanent alteration to collagen conformation179. The collagen 
conformational changes increase collagen resistance to collagenase digestion180. 
Ethanol pre-treatment reduces the water content of the leaflet and affects leaflet 
interactions with water and lipids. The changes to proteins could affect short-term 
mechanical properties of the valve. Ethanol pre-treatment prevents calcification of 
leaflets in rat subdermal implants and sheep mitral valves (circulatory model) but is 
not particularly effective in preventing aortic wall caicification103, 175, 176. Elastin is the 
prominent protein in aortic wall and is not affected by ethanol pre-treatment179. Thus, 
the mechanism of inhibition is probably based on lipid extraction and collagen 
structural changes. 
B3.2.B.2(iii) Tannic acid 
Glutaraldehyde is unable to stabilise elastin and elastin is susceptible to degradation 
and calcification after implantation in animal models118, 174. Tannic acid is a plant 
polyphenol belonging to the galloylglucose family. It forms multiple bonds with 
proteins, particularly those rich in proline such as elastin and cOllagen181 . Tannic 
acid is commonly used in electron microscopy for ultrastructural demonstration of 
elastin fibres. Tannic acid binds to pure elastin protecting it from enzymatic attack 118. 
181. Isenburg et al181 treated porcine aortic wall samples with glutaraldehyde and 
tannic acid. Calcification in the subdermal rat model was three times less in the 
group with tannic acid than the group with glutaraldehyde alone. 
83.2.8(3) Improvement or modification of glutaraldehyde fixation 
Neutralisation of free aldehyde groups with compounds that have reactive primary 
amines and rinsing of tissue after glutaraldehyde fixation reduce calcification in 
animal models97• Increased cross-link density inversely correlates with tissue 
calcification95, 141, 144. However, tissue fIXed using higher concentration of 
glutaraldehyde has higher tissue stiffness182 which may compromise the mechanical 
performance of the bioprosthetic heart valve. The following treatments neutralise 
and detoxify glutaraldehyde treated bioprostheses. 
B3.2.B.3(i) Amino compounds 
Amino compounds such as L-lysine182, L-arginine183 and L-glutamic acid143 neutralise 
and detoxify glutaraldehyde fixed bioprosthetic tissue. Amino compounds create 
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bridges between glutaraldehyde molecules by binding to free aldehyde groups with 
reactive primary amines to improve the cross-link density8, 182, Urazol, a secondary 
amine group, removes residual glutaraldehyde molecules from tissue under acid 
conditions 184, 185, Neutralisation of free aldehyde groups of glutaraldehyde treated 
bioprosthetic tissue reduces calcification in the subcutaneous rat model143 and 
detoxification of glutaraldehyde fixed aortic wall tissue achieves long-term cell growth 
after implantation185, 
B3.2.B.3(ii) Alpha-Amino oleic acid (AOAI) 
AOA is an active neutralisation agent blocking or reducing free aldehyde residues, 
The 2-amino group of AOA covalently binds to free aldehyde groups of 
glutaraldehyde fixed tissue 186 and reduces the influx of calcium ions into bioprosthetic 
tissue186-188. This results in slowing down the initial calcium phosphate formation186, 
AOA also functions as a surfactant to extract phospholipids from the cell membranes 
which reduces the initial nucleation sites for crystallization of calcium phosphate, 
Compared with aortic walls, AOA penetrates more easily into the relatively thin and 
less dense collagenous leaflet tissue 186. The AOA level in aortic walls is not sufficient 
to prevent the calcium influx into aortic wall tissue, explaining why AOA effectively 
mitigates calcification of bioprosthetic leaflets and pericardial tissue in the rat 
subdermal model and the circulatory sheep model, but not aortic wall tissue186, AOA 
is used in FDA-approved non-stented189 and stented porcine aortic valves190• 
83.2.8(4) Tissue fixatives other than glutaraldehyde 
Studies have demonstrated that glutaraldehyde is directly responsible for calcification 
of bioprosthetic heart valves76, n, 142. Thus, even if this is a misinterpretration of the 
truth, the use of tissue fixatives other than glutaraldehyde may have better long-term 
results in bioprosthetic heart valves. 
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84. Hypothesis 
The hypothesis under investigation: 
1. Conventional chemical fixation of antigen reduction through decellularisation 
of bioprosthetic heart valve tissue fails to adequately mask/remove all 
immunogens resulting in both a significant humoral immune response and 
persistent inflammatory response as a direct result thereof. 
2. Targeted masking of these residual immunogens by application of 
immunoglobulin specific for epitopes contained on these immunogens 
together with modification thereof to abolish their opsonising potential prior to 
implantation will mitigate both the host immune response and thus the 
proinflammatory potential of such tissue. 
3. Modification of specific immunoglobulin by enzymatic removal of the Fc 
fragment and application of the resulting antigen binding fragments (Fab 
and/or F(ab'h) prior to treatment of the tissue as one scenario will avoid Fc 
receptor mediated adherence of phagocytes. 
The results of this study will provide a better understanding of the mechanism 
involved in the granulocyte and macrophage/foreign body giant cell dominated 
destruction of bioprosthetic heart valve constructs. Finally I it offers to provide an 
antigen-targeted solution in the quest for the elusive quiescent bioprosthetic heart 
valve. 
35 
C. Proof of Concept 
C1. Characterisation of response against bioprosthetic heart valves 
C1.1. Immune response to bioprosthetic heart valves In patients 
C1.1.A Introduction 
Patients suffering form valvular heart disease typically may undergo heart valve 
replacement surgery to replace their diseased valves. The options for prosthetic 
heart valves involve either mechanical or tissue valves. Tissue valves include 
autografts, homografts or bioprosthetic valves. The homografts and autografts are 
currently the best tissue valves to use, but have limited availability. Of all prosthetic 
heart valves currently implanted, only a third are bioprosthetic heart valves. The 
disadvantage of bioprosthetic valves are that they cannot be used regularly in 
younger patients, because they have a limited lifetime and the patients will have to 
come back for redo operations. In patients over 65 the lifetime of the prostheses is 
generally between 10 191-194 and 15 years 33, 91 which may outlast the life of the 
patient. These valves usually fail due to structural valve damage caused by 
calcification or leaflet tears 93, but immune and inflammatory processes are 
increasingly being implicated in the pathology associated with these failed implants. 
Bioprosthetic heart valve 'rejection' is not similar to the hyperacute rejection of 
transplanted vascularised solid organs, such as hearts, from animal donors and yet 
these prostheses too represent donor-recipient mismatching across the species 
barrier. Bioprosthetic heart valves fail over years and not over days or even minutes 
as in the case with hyperacute rejection. This is largely due to the fact that the 
bioprosthetic valve relies on its structural rather then biological integrity. Heart 
valves are treated with a cross-linking agent such as glutaraldehyde to improve 
biocompatibility by masking non-self immunogens and inducing a full out response. 
The delays in processing as well as the handling of tissue during dissection and 
further processing of the valves results in complete denuding of the endothelium. 
Thus, the subendothelial extracellular matrix, in particular the basement membrane, 
is exposed to a host immune system response when implanted. The initial burst of 
inflammatory cells, usually neutrophils and macrophages, may damage the tissue 
exposing the extracellular matrix even further. After a while the initial immune 
response tapers off to only a few polymorphonuclear leukocytes (PMNs), 
macrophages and foreign body giant cells that persist. These inflammatory cells are 
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phagocytes 195, 196 which have the ability to engulf, digest and remove particles from 
the body as well as fulfil their primary role which is to present antigens 197 to other 
cells of the immune system. Often phagocytes in their attempt to engulf the 
bioprosthetic tissue, will undergo frustrated phagocytosis 198. This process occurs 
when phagocytes fail to digest the indigestible cross-linked prostheses. These 
inflammatory cells have mechanisms to release enzymes and other constituents 199-
201 (nitric oxide, superoxide, hypochlorite and other products of activated oxygen and 
nitrogen metabolism) in the extracellular matrix that may serve to slowly degrade the 
extracellular matrix and further expose more collagen and elastin. These exposed 
and damaged structures of the extracellular matrix may lead to calcification. The 
weakened tissue and structural deterioration of the valves may over time lead to 
leaflet tears and subsequently structural failure of the valve. 
In most studies of explanted bioprosthetic heart valves the investigators do not give a 
detailed report on the inflammatory response and only briefly comment on the 
presence of inflammatory cells 33,91,93, 189, 192-194. This may be due to the fact that 
valves typically only fail after 5 years or longer and the early inflammation may have 
'burnt out' and is often undetected when the valves fail. This early inflammation may 
leave behind 'latent' damage, which may not be identified as failure due to 
inflammation but rather due to structural wear-and-tear. It is only recently that 
Butany et al202 reported on stentless porcine valves where an inflammatory reaction 
may have lead to aortic tissue damage and eventually heart valve failure and 
suggested that it might be a consequence of cellular graft rejection. Only nine 
explanted Freestyle nr porcine aortic valves were identified representing a small 
percentage of the Freestyle no valves implanted annually worldwide. Freestyle TM 
valves are porcine aortic valves cross-linked with glutaraldehyde and treated with 
alpha-amino oleic acid (AOA) as an anti-mineralization treatment. Inflammatory cells 
(lymphocytes, macro phages and plasma cells) were found in all nine explants, 
mostly on the abluminal (adventitial) surface of the porcine aortic wall and the 
interface between the native and the porcine aortic tissues. Inflammatory cells 
(mostly macro phages ) were also seen on the inflow and outflow surface of the 
leaflets. A chronic inflammatory infiltrate was associated with structural damage to 
the aorta and the leaflets, a phenomenon observed relatively soon after implantation 
(4 months) and seen to persist for up to at least 10 years. 
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In order to investigate if inflammation played a role in the failure or structural damage 
of bioprosthetic valves, the histopathology of a small cohort of bioprosthetic porcine 
valves explanted from patients at Groote Schuur Hospital was evaluated. 
C1.1. B Materials and methods 
Five valves explanted at Groote Schuur hospital were used to evaluate the 
inflammatory response. The ex planted heart valves selected were from different 
manufacturers and which failed after different time periods. The valves were all 
stented porcine aortic valves treated with glutaraldehyde and implanted in the mitral 
valve position. The manufacturers employed different anti-calcification treatments. 
Standard histological sections were stained with haematoxylin and eosin (HE) (see 
Appendix A21). Immunohistochemistry for C068 (macrophage marker) and C015 
(granulocyte marker) were performed (see Appendix A20). The sections were 
examined to determine if any inflammatory cells were present. The valves were also 
stained to for IgG, IgM and C3 to investigate the presence and extent of a humoral 
immune response (lgG, IgM and C3). 
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The valves investigated were as follows: 
• Medtronic Mosaic 
o Porcine aortic stented valve fixed with glutaraldehyde and treated with 
AOA (anti-mineralization agent) 
o Two valves explanted after 109 days and 3 years. The valve 
explanted after 3 years was implanted in a 37 year old male and the 
valve explanted after 109 days was implanted in a 77 years old 
patient. 
• Carpentier-Edwards 
o Porcine aortic stented valve fixed with glutaraldehyde 
o One valve explanted after 11 years from a 34 year old female patient. 
• Medtronic Hancock 
o Porcine aortic stented valve fixed with glutaraldehyde and treated with 
T6 (SOS Surfactant - anti-mineralization treatment) 
o Two valves explanted after 19 and 24 years. The patient with the 
valve explanted after 19 years was a 32 year old female at the time of 
the valve replacement. The valve explanted after 24 years was 
implanted in a female patient 26 year old. 
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Cl .l .CResults 
FIgure C· ) Hancock valve (A) before Implant and the inflow (8) aspect of the valve 
after 24 years 
Figure C-2 Hancock Porcine va lve faIled after 24 years A·C· HE Slain O-F CD68 
stam (E was a fluorescent stain where red IS posItIve) . G· llgO stam 
Case 1 A Hancock valve was explanted after 24 years from the mItral posrt lon The 
pallent was a 26 year old female at the tIme of the Implant The mflammatory cells 
(see Figure C·2) were mostly macrophages on the fibrosal SIde of the leaflet A few 
PMNs were VISIble on the flbrosal side and a few Infiltrated Into the spongIosa. There 
were a few lymphocytes present on the f,brosal side olthe va lve. The valve staIned 
pOSitive for IgO throughout the leaflet. bUI II was Ihe lowes! Inlensrty of the valves 
staIned 
Figure C-3 Hancock valve (A) before Implant and the oulflow (8) aspect and the 
InHow (C) 01 the valve after 19 years 
Figure C-4 Hancock Porcme va lve failed after 19 years A-C HE stain D-F COOS 
slam, G-t IgG 51all1 
Case 2 The se<:ond Hancock valve was e~planted after 19 years The valve was 
Implanted In the fT\I!ral poslhon of a 32 year femaie patoent This valve d,d not 
present wrth many Inflammatory cells but those pi'esent wele mainly InfI ltrated into 
the spongKlsa of the valve (see f'gure C-4) The Inflammatory cells Involved a 
comblnalJon of macrophages and granulocytes The spongiosa slallled posrllve lor 
IgG and was mostly aSSOCiated With the extracetlular matr,~ but not WIth the cells 
" 
F!Qure COS Carpenher·Edwarc!s valve (A) before Implanllhe oUlfiow (8) aSpetl and 




Figure C-6 Carpentier-Edwards porCine va lve falled after 11 years A-C HE sla,n 
O-F CDSS stain H-t Ham56 stain, J-L IgG stam 
Case 3 A 23 year female pallent wrth a Carpentier-Edwards va lve implanted In the 
mitral poSlilon and explanted after 11 yea~ The fibrosa had ,nflammatory cells (see 
Figure C-6) alt along the edge that ConSIsted 01 PMNs, macrophages. foreIgn body 
gIant cells. lymphocytes and plasma cells The leaflet st~lIned pOSItIVI for tgG on the 
ventncuJans edge and also w~hln the !Issue 01 the spongIosa There was no clear 
IgG stainIng on the edge 01 the f,brosa 
Figure C-7 MosaIC valve (A, B) before Implant and the outflow (C) and mflow (0 ) 
a'oedl aftl!tf 3 ye~ 
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Figure C-8 MosaIC Porcine valve failed after 3 years. A-C HE stain, O-F C01S 




Figure C-g MosaIC Porone valve failed alter J yeill1i A-C tgG stil ln o.F 19M slain, 
G-! C3 Slilln 
Case 4 A MOS;tlC valve was explanled aher 3 years Irom iI male patient a9ed 37 
vears 31lhe lime 01 Implant The valve had marked numbers 01 H'Ifiammalory cells on 
the fibrosal sulfate of the leaflet (see Figure C-9) Mo!ll of Ihe ,nftammalOfY cells 
were granulocytes but illso Included plasma cells lymphocytes itnd maCfophllges A 
few foreign body giant cells were also obsel'lled on the outside 01 the .., flammatory 
om The venUICUrans had leu Iflllammatoon but all of the above mflammatory cells 
were present. The valve leaflet stained strongly poMlVe Nl aU Ih,ee layers lor both 
IgG and CJ (complement) (see FogUfe Cog) There was no poSitIVe 51,IInmg for 19M 




Figure C_IO Mosaic va lve (A, 8) before Implant and the outflow (C) aspect of the 
valve after only 109 days 
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Figure C-It MosaiC valve that fa,led after 109 days A-C HE staIn D·F COO8 
Still n ) 
Case 5 The valve was explanled after Onlt 109 days because one leaHet was 
sutured onto the sewing nng (see Figure ColO) The valve had only scanty 
Inflammatory cells (see Figure C-l1) Macrophages, lymphocytes and granulocytes 
wele present In the spongiosa and towards the flbrosal side of the leaflet, but not On 
the fibtosal surface of the leaflet ThiS valve was Included because It showed the 
Inflammation of the valvf! after only 109 days 
Table 1 Inflammation of the leaflets of explanted bioprosthetic heart valves from 
patients 
Valve Inflammatory cells Fibrosa Spongiosa Ventricularis 
Hancock PMNs + + -
(24 years) Macrophage + + -
Foreign body giant cell - - -
Lymphocyte + - -
IgG + + + 
Hancock PMNs - + -
(19 years) Macrophage - + -
- .. - - -
Lymphocyte - - -
IgG - + -
Carpienter PMNs + + -
Edwards 
Macrophage + - -
(11 years) 
Foreign body giant cell + - -
Lymphocyte + - -
IgG - + + 
Mosaic PMNs + + + 
(3 years) Macrophage + + + 
Foreign body giant cell + - -
Lymphocyte + + + 
IgG + + + 
Mosaic PMNs + - -
(109 days) Macrophage + - -
Foreign body giant cell - - -
Lymphocyte - - -
IgG N N N 
(N: not stained for IgG) (+: cells present, -: cells absent) 
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C1.1.D Summary 
Clinical studies have shown that macrophages are the main invading phagocyte 
which may play a role in degrading collagen. In another study the initial steroid 
therapy after heart valve replacement in patients also lowered the occurrence of 
calcification of the bioprosthetic valves163• The steroid therapy may have reduced the 
initial inflammatory response to the valves and thus protected the valves from 
structural damage. Graft-specific antibodies were present in patients confirming that 
there is a humoral response to the tissue as weW3, 94, 157, 163. It is only recently that it 
has been reported that an inflammatory reaction may have lead to aortic tissue 
damage and eventually heart valve failure and suggested that it might be a 
consequence of cellular graft rejection202. In this study the small cohort of 
bioprosthetic valves explanted at Groote Schuur hospital showed that inflammation 
might have played a role in their failure. 
The inflammation of the valves explanted at different time periods showed that 
initially the valves had an innate type inflammation dominated by neutrophils. There 
was a strong humoral response as seen with the strong positive staining for IgG. 
The IgM response was less obvious suggesting that the response was not simply a 
preformed antibody response as is the case with hyperacute rejection of vascularised 
xenogenic organ transplants. Bioprosthetic tissue is typically denuded of its 
endothelial lining as a consequence of processing and thus the porcine vascular 
endothelial xenoantigen, galactose-[alpha]-1,3-galactose (alpha-Gal), is depleted, at 
least with respect to the valve's lumenal surface. Preformed alpha-Gal antibody 
which is mostly responsible for early hyperacute rejection seen in vascularised 
discordant donor-recipient solid organ transplants between pigs into human (or 
primates) as a result does not playa similar role in heart valve replacement. Chen et 
a1203 showed that although cardiac microvascular endothelium strongly expressed the 
galactose [alpha]-1,3-galactose antigen, galactose [alpha]-1,3-galactose was not 
detected on the endothelium of porcine aortic and pulmonary valves and this may 
also result in porcine valves being protected from xenograft rejection in primates. In 
contrast another group reported the presence of the immunogenic alpha-Gal-epitope 
on fibrocytes interspersed in the connective tissue of porcine valves. They also 
showed that glutaraldehyde-fixation at concentrations used for commercial use did 
not diminish the response to the alpha-Gal epitope. Their finding of a significant 
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increase of alpha-Gal IgM antibodies in patients after implantation with bioprosthetic 
heart valves suggested a response specific against the xenograft. 204. 
The inflammatory cells were mostly found on the fibrosal aspect of the leaflets. This 
surface is more protected against the shear stress exerted by the blood flow than is 
the case with that of the ventricularis. In some cases the inflammatory cells 
infiltrated into the spongiosa continuing inflammatory cell degradation of the tissue. 
In contrast there were only a few inflammatory cells on the blood surface of the inflow 
side of the valve. The ventricularis is exposed to a more laminar blood flow 
compared to the fibrosa and it is therefore more difficult for the inflammatory cells to 
adhere. This is similar to what is seen on the blood surface of the aortic wall 
compared to its adventitial surface. 
Inflammation included neutrophils, macrophages, lymphocytes and plasma cells with 
only a few foreign body giant cells. The types of cells found suggest that the 
response was not limited to an initial non-specific acute response, but" that it had 
evolved into a more specific form. The presence of IgG on all of the layers of the 
leaflet indicated that there was a clear well-defined humoral response against the 
bioprosthetic tissue. Most of the inflammatory cells also present have Fc receptors 
205 capable of recognising the Fc part of the IgG bound to, and thus opsonising, the 
tissue and leading to a stronger and more specifically targeted response. 
Even though this was only an anecdotal study of a limited number of clinically 
explanted valves, it nevertheless demonstrated that fixation of porcine heart valve 
tissue with the low concentration of glutaraldehyde used in contemporary 
bioprostheses was not adequate to sufficiently mask the antigens from the host 
immune system and that a clear cellular inflammatory response was present long 
after the valves were implanted. 
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C1.2. Immune response to bioprosthetic tissue implants in animal models 
C1.2.A Introduction 
Animal models used to investigate the biocompatibility of bioprosthetic heart valves 
are typically either circulatory 200 or noncirculatory, as in this case a subdermal 
model. In the circulatory model the whole valve may be implanted and its 
performance can therefore be investigated in a blood flow environment, thus 
simulating how it will be used clinically. In the subdermal model only the host 
response and calcification potential cian be investigated. Indeed subdermal models 
are regularly used to test different anti-calciflCation treatments 207, but not the full 
biocompatibility or functionality of the design of the valve. 
In this study we examined the immune response to bioprosthetic valves in both 
circulatory and subdermal animal models to compare inflammatory responses to 
bioprosthetic tissue. 
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Cl.2. B Materials and methods 
C1.2.B(1J Circulatory models 
Cilacma bilboon 
Pig aortic wall was harvesled from healthy pigs at the abattOir (see AppendiX AJ) and 
treated with 02% glutaraldehyde (see AppendiX AT2) after a 48 hour delay al 4"C 
The trealed pig aortic wall tissue was used to fabricate vascular tubes sIZe 
approximately 2 em, small enough t~ Implant end-la-end on the W,ac POSItiOn 01 the 
baboon (see Figure C·12) These tubes wele retneved after 42 days 
.. 
I • 
Figure C-12 The baboon iliac model The top right picture show, the graft Implanted 
In the graft positi on The bonom right picture shows the graft explanted and spi lt 
longitudinal ly 
The explanled tissue was fixed ir 4",(, paraformaldehyde processed and wax 
embedded In blocks for sectoonlng {see AppendiX A19} and stained Wll h HE (see 
Append iX A21 J. Immunohistochemistry (see AppendiX AlO) for COOS (macrophage 
marker). Abcam (macrophage marker). and IgG were also performed The sections 
were Investigated 10 determine the e~tent and type of Inflammation present 
VeNel monkey 
PorCine artenes, SIZed approximately 3 em were harvested at the abattoir from 
healthy pigs (see Appendix A3) and treated with 0.2% glutaraldehyde (see Appendix 
Al2) after a 48 hour delay at 4' C After treatment the porcine arteries were 
Implanted end-Io-end In the ihac pos~lon of the vervet for 42 days (see Figure C-13) 
Figure C-13 The porcme artery Implanted In the Ihac posllOn of Ihe veNel monkey 
Retrieved arteries were fixed in 4% paraformaldehyde The samples were 
processed and blocked in wax (see Appendix A19) SectIOns were stained wrth HE 
and Brown and Brenn (B8) (see AppendiX A2l) The BB slain IS normally used 10 
determine bacterial Ioadmg of the tissue but also provides good definitIOn of the 
nudei of InfiammalOry cells, thus aiding In their identification 
C1.2.B(2) Subdermal imp/am models 
Porcme aortic !Issue was haNested al Ihe abanolr from healthy pigs (see AppendiX 
AJ) Coupons, sIZe 12 mm, were cut from the porcine aortic wall and lreated with 
02% glutaraldehyde (see AppendiX A 12) after a 48 hour delay al 4' C The coupons 
were Implanled subdermally Into pouches created by blunl d,ssec\lon on the ventral 
aspect of the abdomen of the VeNel mon~ey . and the dorsal subscapular re9,on of 
rabbits and rats 
The coupons were retrieved and fixed In 4% paraformaldehyde after 42 days The 
samples were processed and blocked In wax (see AppendiX A19) Olfterenl 
Immunohistochemistry stains were performed lor Ihe dlHerenl subdermal models 
Ve/Yel monkeys 
SecMns were stained With HE (see AppendiX A21) and immunohIstochemIstry (see 
AppendiX A20) lor IgG and C3 (complement) was performed 
New Zeal.md V\IIPlle@bblls 
Sect ions were stained WIth HE and 86 (see Appendix A21) and 
ImmunohlstochelTllstry (see Appendix A20) lor C3 (complement), IgM and IgG was 
performed 
LOllq EyilllS rars 
Sect ions were staIned wrth HE and 66 (see Appendl~ A21 ) 
Cl .2.C Results 
C1.2.C(1} Circula tory models 
Cl .2.C.l (i) Chacma baboon 
The Inflammatory cells on the Intimal side (see Figure C-16) of the implants were 
predominantly fo reign body giant cells that hned up agaInst the lumlnill surfilce 
There was also host tissue o~ergrowth (pa nnus) on the Int imal Side (see Figure 
C· 1Sj o~ergrowpng the for!!jgn body g iant cells The pannus tissue rtself included 
PMNs. plasmi! cells and lymphocytes On the bJood surface Side 01 Ihe pannus. 
repopulation of endothelial cells was seen 
The Inflammatory rim (see F;gure C-14) on Ihe ad~ent~i i!1 Side was dominated With 
PMNs. eosinophlls, macro phages plasma cells lymphocytes and fore.gn body giant 
cells In contrast With the intima and ad~entl\la l surfaces of the artery, were there no 
Inflammatory cells In Ihe media 
IgG slalnmg (see F.gure C-16) was observed on the both the intimal and adventit ial 
surfaces respectively but did not penetrate Inlo the medii! IgG stain ing was most ly 
colocahsed With Ihe macrophilges on the adventitial side and W1\h some inr.ltratlon 
Into the media On the intimal sllrface the staining was mostly on the surface ilrea 
With hmMd 'nfiltration Into the media There was not posilive staining fOf IgG In the 
media 
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Fi\lure C-14 8aooon advenlitJal SIde 01 the po<one aortIc rubes A HE st.illn B ar'Id 
C Abeam stain 0 - E COO8 
Figure C-15 Baboon model staIned for IgO A and B IS on the inllmal sIde and C 
and 0 IS slalnlng on lhe adventItial s>de 
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FIgure C-17 Porcme aortic tube e .plan ted from the baboon after 42 days hlstolog~ 
sectLons 51.lIned W1th HE AlOe IS on the Intimal Side of the tube, D (0 E IS the 
pannus on the intimal side of the lube and G \0 liS the advenMial side of the tube 
C1.2.C.1(ii) Vervet monkey 
There were 01"11)' a few macmphages and fOfelgn body giant cells on the Inllmal 
surface WIIhout any pannus overgrowth (see andFlQure CI8 and Figure C19) 
There was no observed ",filtratlOn of Infiammafory cells III the media but there was 
some degradahon of tissue 01"1 the advent",al side 
The mflammalory cells (see FIgure C-18 and Figure C19) 01"1 the adventitial SIde 
were a combination of PMNs macrophages. lymphocytes. plasma cel ls and foreign 
body giant cells 
, ;,"';>; 
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F,gure C t8 V8fVet anery slamed wrth HE (A and B) and BB (C) A, Whole graft. B 
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Figure C Ig Vervet anery stained WIIh HE (A and B) al'ld BB (e l A, . 'NhoIe graft 8 
and C Advenlttlal side (M - Macrophage, F - Foreign body giant cell L 
Lymphocyte P - Plasma cell N_ Neutrophil) 
e 1.1.e(1) Subdermal implllnt model 
e 1.2.e.2(i) Verve! monkey 
The IfIflamrnalory cells on the Intimal surface were PMNs lymphocytes. 
macrophages and foreign body glanl cells IgG and CJ stained positIVe 00 the edge 
01 the media 
On the CUI edge of the coupoo there were some macrophages and IgG posItive 
51alolng assOCIated WIth these cells There was only scaHered positIve sta,",og lor 
CJ IhroughoUl the med,a 
The foretgo body Qlam cells were obServed Imed up directly agaInst lh ls adventIt Ial 
sorface 01 !he tISsue The loflammalory om outs.de the lore lgn body g'ant cells 
Included PMNs rnacrophages Iymphocv1es aod plasma cells There was also 
POSItIve stamlflQ lor C3 at the medial mterface 
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Figure C-20 Glutaraldehyde fixed porcme aona coupons explaoted Irom ~er'lel 
mon~eys A and C HE slains B and 0 BB slalns A and B ,"IImat SIde C and 0 
advenldlill stde 
" 
F'gure C-21 Glularaldehyoe f,xed porcine aona coupons explanted from Vl!fVet 
monkeys ;., and D HE slain Band E IgG Slam and C and F C3 stain A 10 C 
mtlmal side and 0 to F. adventlt,al sKie 
C1 .2.C.2/ii) New Zealand White rabbit 
On the Int,mal surface macrophages with a few foreign body giant cells formed the 
main Inflarrmatlon on the edge of the tissue Only a few PMNs and plasma cells 
were seen on Ihe Intimal sode There was IgG and IgM positive staining on the 
surface of Ihe tissue. IgG and IgM sta ining was mostly cOlocallsed Wllh Inflammatory 
ce lls IgM was spec'focally associaled wllh plasma cells ana PMNs The 19M may be 
an artefact of Ihe IgM staining the plasma cells surface Immunoglobuln or II may be 
due to blndl1g to Ihe Fc receplor ollhe PMNs 
There were no Inflammatory cells In the media and no IgM posit,ve staining The C3 
stained In a5SOCIatiOn With cells In Ihe media The IgG posilive stalnlrg In the media 
was associated wllh calCification depos~s In the coupons 
Macrophages and foreign bodies hned Ihe edge ollhe adventitial Side 01 the coupon 
The Inflammatory celis included also PMNs. iymphocytes and plasma cells IgG.lgM 
and C3 stamed posl!lve on the surface 01 the advenlrt",l tissue 
Flg"re C·22 Adven~1Ia1 side 01 gI"lill'illdehyde r'~ed POfCIrn! aorta coupons eKplanled 





Figure C-23 Adven!~,a! side of glutaraldehyde fixed porcine ao<la coupons explanled 
from (abbots A to C HE slaon 0 10 E BB stOlon F C3 Slain G 10 I IgG stam J 10 
L IgM slain 
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Ftgure C-2" Inllmal SIde of glUlaraldehyde f,xed porone ilona coupons e~planted 
from rabb'ts A 10 C HE stain 0 \0 F Maaophitge sla in G to t tgG Slain J \0 l 
19M slain 
" 
C1.2.C.2Iiii) Long Evan!! rat 
The inflammatory cells mostly observed were lymphocytes W11h a few macrophages 
ilnd PMNs on both sides 01 the coupon There were no mllammiitOfY cells wlthm the 
media and no infinration of the ~flammMOfY celts ~to the media 
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Figure C.25 Glutaraldehyde flxea porCIne aOl1a coupOns eKplanted from rals A and 
B Intimal Side C ilnd 0 iICIvenU!.lal side A and C HE stam B ilnd 0 BB stalll 
FlQIJre C.26 Glutarilldehyde fixed porcme aona coupons explanted from ralS A and 
B Inllmal Side Can-dO adventitial s,de A and C HE stain Band 0 aa Slam 
Table 2 Summary of the inflammation of the different animal models 
Model Animal Intima Media Adventitia 
Circulatory Chacma Ly, PMNs PCs, No inflammatory PMNs, Eos, Mq., 
baboon FBGCs, ECs cells PCs, Ly, FBGCs 
Pannus No Pannus No Pannus 
IgG NoigG IgG 
VelVet Mq., FBGCs No inflammatory PMNs, Mq., Ly, 
monkey cells PCs, FBGCs 
No Pannus No Pannus No Pannus 
Subdermal VelVet PMNs, Ly, Mq., Mq. PMNs, Mq., Ly, 
monkey FBGCs PCs, FBGCs 
IgG,C3 IgG,C3 C3 
New PMNs, PCs, Mq., No inflammatory PMNs, Ly, PCs, 
Zealand FBGCs cells Mq., FBGCs 
White rabbit 
IgG,lgM IgG,C3 IgG.lgM. C3 
Long Evans Ly. Mq., PMNs No inflammatory Ly, Mq.. PMNs 
rat cells 
(Ly: Lymphocytes, PMNs: polymorphonuclear leukocytes, Eos: eosinophils, Mq.: 
macrophages, PCs: plasma cells, FBGCs: foreign body giant cells, ECs: endothelial 
cells) 
C1.2.D Summary 
In this study we showed that different animal models all elicited an immune response 
to glutaraldehyde fIXed porcine tissue. The response was further investigated in the 
Rabbit model. A smaller animal model which is more cost effective with less ethical 
consequences than using the primate species with a similar inflammation pattem to 
the primate species. 
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In different animal studies investigators had a few findings that may link inflammation 
and calcification. These findings were the following: 
• Heterologous tissue calcifies more than homologous tissue114 
• Grafts incubated in graft-specific serum before being implanted had three 
times more calcification 161 
• Tissue fixed in glutaraldehyde elicit both cellular and humoral responses 152, 
and 
• Increasing the glutaraldehyde concentration to 3% to better mask the 
antigenicity lowered the calcification of the grafts141.144. 
The circulatory model has an advantage over the noncirculatory model in that the 
tissue is exposed to the blood environment. The shear stress of the blood flow 
reduced adherence of inflammatory cells on the intimal side compared to the 
adventitial side. A similar pattern was seen in the noncirculatory model where more 
inflammatory cells adhere to the adventitial side of the coupons. This is clearly 
therefore not only the result of shear stress, but that the adventitial surface with its 
loose collagen has potentially more exposed and accessible antigens than the 
smooth compact surface of the intima. The inflammatory cells were similar in all the 
models, except in the rat model where the inflammatory cells were dominated by 
lymphocytes. In the other models the inflammatory cellular response was dominated 
by granulocytes and macrophages. The humoral response was observed in both the 
Circulatory and noncirculatory models. Most of the inflammatory cells have Fe 
receptors and the presence of IgG opsonising the surface of the tissue may lead to c 
more specific response. 
The rabbit subdermal model proved to be a good model to evaluate the inflammato~ 
response, since it showed similar inflammatory cells to the two Circulatory models. 
Even though it was a subdermal model without the shear stress of blood flow, the 
coupons subdermally implanted into the rabbit showed more inflammation on th9 
adventitial side than on the intimal side. This is similar as to what was seen in the 
circulatory models. As a subdermal model the rabbit did not show any pannus, but 
there were foreign body giant cells present similar to the circulatory models. Tile 
rabbit is also a less expensive model to evaluate than both the baboon and vervet. 
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Although they provide a better estimate of the response in humans, ethical 
consideration restricts the use of primates in experimentation. Ethical considerations 
make the choice of animal model more complex and the researcher must consider 
the use of animal models carefully. Due to the complexity of the immune response 208 
animal models, however, remain crucial to bioprosthetic research. The ideal is to 
use the rabbit as a screening model and the primate as the pre-clinical model. 
C1.3. Acquired immune response in rabbits to porcine tissue 
C1.3.A Immunisation of rabbits with porcine tissue 
C1.3.A(1) Introduction 
Rabbits were immunised with different porcine valve tissue preparations to 
investigate their potential to elicit an immune response. The sera of the animals 
immunised were used to compare IgG binding to fresh porcine aortic tissue treated 
with glutaraldehyde. Serum from rabbits before immunisation was used to evaluate 
the possibility of preformed antibodies with specificity or cross-reactivity for the 
porcine tissue used for immunisation. 
Three preparations of porcine aortic tissue were used for immunisation: 
• Fresh porcine aortic wall was used to evaluate the overall response to 
porcine aortic tissue. 
• Decellularised porcine aortic tissue was used to evaluate the extent of 
immunogenicity of the extracellular as opposed to cellular components of the 
aortic tissue. 
• Purified porcine fibronectin was selected, because it had previously been 
shown to elicit an immunoglobulin response in porcine aorta. 
C1.3.A(2) Materials and methods 
C1.3.A.2(i) Preparation of tissue for immunisation 
Different homogenates for immunisation were prepared. The tissue of the porcine 
aortas was homogenised into a powder form to disturb the structure and render the 
epitopes more accessible for immune system recognition. 
Fibronectin was isolated from the plasma of porcine blood. The structure of soluble 
plasma and insoluble cellular fibronectin appear to share similar common structural 
organisation 209. It is reported that there are three regions with differences in the 
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polypeptides of plasma and cellular fibronectin. Plasma fibronectin does not result 
from posttranslational proteolytic modification of the cellular form 210. They are 
however very similar or at least not distinguishable in immunological assays, amino 
acid and carbohydrate compositions, peptide maps, electrophoretic mobilities and 
spectrophotometric properties 210. Thus, using plasma fibronectin would therefore 
elicit a similar response as cellular fibronectin. 
Porcine aorta 
Fresh porcine aortas were collected from the abattoir (see Appendix A3) and the 
aortic wall was divided into smaller fragments and frozen in liquid nitrogen. 
Fresh porcine aortas collected from the abattoir were extensively washed in solutions 
with SDS and Triton X-100 detergents to remove cells from the tissue ideally leaving 
behind only the extracellular matrix. This process was performed by Medtronic's 
Heart Valve Division in Sante Ana, CA, USA (see Appendix A4). After receipt of the 
decellularised tissue, it was rinsed in PBS (pH 7.4) and the wall divided into smaller 
fragments and frozen in liquid nitrogen. 
The frozen fresh porcine aortic wall and decellularised aortic wall fragments were 
homogenised (see Appendix A5) with a homogeniser. Small frozen tissue fragments 
were placed in an ice-cold stainless steel tube (cooled in liquid nitrogen) with two ice-
cold stainless steel ball bearings (also cooled in liquid nitrogen). The tissue is 
shaken at high speed for only a few seconds to prevent the tissue from thawing. The 
tissue was pulverised into powder form. The powder was pooled in a mortar cooled 
with liquid nitrogen and mixed with a pestle into a homogenous mix. The 
homogenous powder of the two groups was stored separately at -80°C. 
Fibronectin 
Blood was collected from normal, healthy pigs and the plasma (see Appendix A2) 
was used for isolation of plasma fibronectin using affinity chromatography (see 
Appendix A11). Pig plasma (100 ml) was applied to a gelatin-agarose column (see 
Appendix A11 b) and since fibronectin has a gelatin-binding domain, it was able to 
bind the gelatin ligand. All the other plasma constituents remained unbound and 
were eluted from the column. The fibronectin was finally eluted from the column 
using urea causing it to briefly denature. The pooled fractions of fibronectin were 
subsequently dialysed against double distilled water to remove the buffer salts and 
urea. The pure fibronectin was freeze-dried and finally stored at -80°C until use. 
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C1.3.A.2(ii) Preparation of emulsions for immunisation 
Emulsions were prepared for immunisation from suspensions of the powdered tissue 
in sterile saline and Freund's incomplete adjuvant in a 1:1 ratio (see Appendix A6). 
The porcine aorta homogenate and decellularised porcine aorta homogenate were 
prepared from 10 mg of the powder respectively. The powder was insoluble and 
mixed with sterile saline (O. S ml) before adding the Freund's incomplete adjuvant (O. S 
ml). 
Fibronectin (1 mg) was first dissolved in sterile saline (O.S ml) before adding the 
Freund's incomplete adjuvant (O.S ml). 
A final volume of 1 ml emulsion per animal was prepared from each immunogen 
preparation using Freund's incomplete adjuvant. The emulsions were stored in 
sterile injections at 4°C ready for immunisation. 
C1.3.A.2(iii) Immunisation of the animals 
Eight New Zealand White rabbits aged S weeks were used for immunisation. Four 
animals were immunised with porcine aorta homogenate, three animals were 
immunised with decellularised porcine aorta homogenate and one animal was 
immunised with fibronectin homogenate (see Figure C-27). The emulsions were 
injected subcutaneously at two sites (O.S ml each) on the animal's back with eac~ 
animal receiving a total dose of 10 mg. 
Fibronectin was injected at four sites (0.2S ml each) with each animal receiving a 
total dose of only 1 mg. 
After 14 and 21 days respectively the animals were administered boostEl" 
immunisations of the same dose. Test blood (S ml) was drawn from an ear vei, 
immediately prior to immunisation and immediately prior to booster immunisations tD 
monitor antibody production. The animals were killed after four weeks and a large 
volume of blood collected by cardiac puncture into blood collection tubes and sem 








POfClne plasma I,broneaon 
Irnrnunose rabb,ts on day 1 
and booster ener 14 and 21 days 
Cdteel blood samolO$ on day 0 (ley \4 (lev 2\ end eli the blood on dey 28 
F'gure C-27 Immunlsallon of rabbns WIth drtferent pOrcme ,mrTllJnogens 
Care of Arnmais 
All anaesthetrc and surgICal procedures Wefe approved by the anlmet e!nics 
comm,Uee of the UnNefsrty of Cape Town and complied with the -PrinCIpals of 
Labo<alory Care and tile guidelines for the care and use of labo<atory ammals 
" 
Cl .3.A.2( iv) Western blo t detec tion of tislue s lM'c ific antibodies 
SDS PAGE electrophoresIs IS a sIZe-based separation 01 protelos 50s IS an 
anIonic detergent that DH'Ids to most soluDle protl!lfl mole<;ules 111 aqueous soluhon 
over a WIde pH range PolypeptlCle chaIns bInd amounts of 50s proporllOoal to the 
sIze of the molecules The net negahve charge of the protelOS IS strongly attracted 
towaros the anode In an eleetncal freld The densrty of Ihe polyacrylamide gel 
determ~es Ihe mIgratIon rate of the pfotetn wdh larger molecules migratIng slowel 
than smaller ones 
Western 0I01llllg Involves electloblottlng whICh uses a electnc current 10 traos/er the 
separated Plotell1$ from the gel onto the PVDF membrane whICh can be detected 
uSIng latlelled iJIlhboOy The PVOF membrane bonds all proteIns non-speer/lcally 
bitSed upon hydrophobIC InteractIOns as well as charged Inieractrons between rhe 
membrane and protetn The Pfoterns move from the gel onto the PVOF membfane 
whIle maintaining the organisatIOn of the PIOI81ns separated on the SDS 
polyacrylamide gel The PVDF membrane has the abolrty to bInd both the target 
protellls and antIbodieS To prevent Interac\lO(lS between the membrane and the 
anllbody used for detection rhe membrane was blocked for non-SpeClrK; btndl"9 by 
plaang the membrane 111 a dllule solUtion of prOlelll such 8S a non-fat dry mIlk and a 
detergent sudl as Tween 20 The translelred Pl'Ol&mS were used to detect antibody 
productlOll In the serum of the anImals ImmunlSed wtth porcine immunogens 
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Figure C·28 The trans1er 01 protePlS to a PVDF membrane and WesteHI Blot 
Fresh porcine eortie ,lI/rilef Western blot 
A prole ... extract was pl'epared Irom homogenlsed unfixed pOrcme aortic wall hssue 
by overnight eJCtf<1lcltOn In a denatUring buffer (see Append!> Al) The protem 
concenlta\lon 01 the extlad supernataJl1 was oelerm,ned using a detergent 
compa1ible protein de1ectlOn kIt ((DC protein assay Blc-Rad) (see Appendl lt AS)) 
The eJrtract was electropnoretlCaMy separated on gradlet1\ 50S polyacrylamide gels 
(4-20%1 to achieve good separatIOn 01 1'1,gt1 molecular weight prOle Ins Whi lst avoiding 
loss 01 smaller prDlems (see Appendl~ A9) The separated proteins were transferred 
omo a PVDF membrane and the membrane was blocked O~errltght In 5% molk 
powder on nBS buffer at 4 'C to prevent any non-specIfiC binding of protems and 
antibodIeS to the PVDf membrane western blot (See Appendl~ AtO) was 
perlormed With II"le sera obtained from The Immunlsed rabbits The sel\lm samples 
were diluted 1 100 In 5% ITUlk powder TIBS buffer for dete<;Ilon the secondary 
" 
antibody goal snh-rabblt Immunoglobulin conjugated 10 horseradIsh pero~ldase (BID-
Rad cal 1\0 17~515) was dIluted I 3000 and applIed 
Fl'bronectln Western blot 
PorcIne l ibrOl1et\ln was dlssol\led In PBS and eJeclrophorellcal ly separaled on 
gradlf!f1t 50S polyacrylamrde gels (4-20%) 10 separale Ihe hrgh molecular weight 
(,broned", (440 kO cons~l lng of two 220 kO ,Subunrts) and any fragments thereOf 
(sea AppendIX Ai) The separated proteIn was blotted onlo PVDF membranes and a 
"""Iar Western bioI (See AppendIx A 10) wIth the sera obtarned from the Immunrsed 
rabbits was performed (see above) 
Cf.3.A(J) Results 
Cl.3.A..3(1) Western blot detect ion of antibodies Irom immunised serum 
The 50S elflracllOl1 process 01 unfixed porCIne aOl1IC wall IIssue showed a WIde 
ra"IIB 01 hrgh and lower molecular werght proteIns after separalJOn on a gradIent 
50S polyacrylamide gel The Western blots as shown In Figure C-29 and FIgure C-
30 clearly showed lhat the rabbits fOlmed antlbodres agalost the proteIns extracted 
from porcrne aoroc wa ll and porcine rrbronectln f!agmems As shown In FIgure C-29 
arid Figure ColO these antIbodies were not present rn the Sefa collected from Ihe 
rabb~s belore ImmunISation (control sera) 
" 







r,gu,e C·29 Anllgen f • .,sn par,,,,e eone e><tree! l .. nes e llemete pre ·" ... ",,,,,,, 
serum and serum after ImmUniSililOn lane 1 and 2 sera of one rabbit Inununlsed 
against lil;lroneclll'l Lanes J 10 8 sera of the three I1lbbols tmmumsed aga!flsl 
decellulansed pore..,., ao"o<; tISSU., lanes g to IS sera of the four rabbots Immunlsed 
agalnsl fresh porelne aonK: wall t ISSue 








" porCine aorta 
Figure C·lO Anllgllf'l porCine flbroneclln lanes alternate pre-Immune serum and 
serum after ,mmumntrOn lane 1 and 2. sera of one rabbot Immunlsed agall'>sl 
libroneclll'l . lanes 3 to 8 Sela of the three rabbits Immunrsed agamst decellulallsed 
porCll'le aortIC tissue lanes g to 16 sera of the four rabbots Immun'sed agarnSI fresh 
porcrne aortIC wa ll \lswe 
C1.3.A(4) Summary 
This study confirms the development of an immu ne response to porcine aortoc va lve 
tissue There IS also clear evidence that removal of the cells did not render the 
tissue non'Immunogenic and that the extJaceliular matn~ components contmued to 
ellc,t a response on the animals Immunosed With decellulansed porCine aortic valve 
IIssue The speCifiC anllgen, porc ine plasma fibronect ln. elicited a response and was 
specifiC for many antigens e~tracted from porcone aortiC valve tissue as well as for 
the plasma porcine fibronectln and fragments thereof Thus. the Immunogenoclty of 
pOrCine aortic valve tissue IS not hmlted onl~ to the cells but that the e~tracellular 
matn~ components also playa role The strategy to remove the cel ls from pOrcine 
aortIC vatves In order to render them non-ImmunogeniC IS not suffiCient and Will have 
to be combined wrth an additional strategy to mask the reSidual immunogenoClly of 
the extracel lular matrix Fibronectin, a gl~coprotein. IS a major constituent of the 
basement membrane and therefore represents the first level contact with the host 
Immune system It was shown that flbronecton IS a Significant contributor to the 
Immune response A further study to identify the ant'gens present on the e~t racellular 
mat"~ of the porc",e aOr1a Will help 10 understand the immune respOnse beller and 10 
fi nd strategies to mask specific antigens 
C1.3.B Determine binding of immune sera to commercia l bioprosthetic porcine 
tissue (0.2% glutaraldehyde) 
C1.3.B(1) Introduction 
It was Imporlanl to demonstrate that lhe acquired Immune response seen In the 
rabbits immunlsed wrth the diHerent porcine tissue preparations was also specifIC for 
intact pOrcine bioprostheses Treatment of pOrcone valves With 0 2% glutaraldehyde 
was used 10 repllcale contempOrary commerCial blOprosthellc valves. 
C1.3.B(2) Materials and methods 
C1.3.6.2( i ) Tissue preparation and fi~ation 
Fresh porcine aortas were collected from the abattou (see AppendiX A3) The va lves 
were fi~ed In 0 2% glutaraldehyde (see Appendl ~ A I I) and processed on 4% 
paraformaldeh~de for immunohistology (see Appendlt A 18) 
Fresh pcn;.ne aortK; valve was fixed in 10% forma lin (see Appendix All) and 
processed lor Immunohistology (see Appendix AIS) The ELMAS stain fS a 
hlstoc;hemocal Slain for collagen elaslIrl and muscle This Slam (see Appendix A20) 
was pefformeo w~h fresh pOrcine aortic valve to Identify the d,stnbutlon of collagen 
al'ld elastin 
CI .3.B.2(ii) Immunohistochemistry 
The Immune sera from the Immunlsed groups were used to stam for IgG {see Figure 
C-JI on 02% glutaraldehyde fixed porCine aort ic valves (see Appendix A19) The 
sera collected from animals before ImmumsatlOrl (control sera) were used 10 
datarmlne the baseline response of the animal before Immunisation and 10 detect if 
arlY preformed arlllbodl8s agaonsl porCllle aort l(; wall were present Serum was 
applied 10 the sectoons Ht I 100 dlluIIOrlS In TIBS as the PJimary antibody The 
secondary arlllbody gOllI ant ... abblt Immunoglobutin conjugated to horseradISh 
peroxidase (Blo-Rad. cat rlO 170·6515) was diluted 1200 and apphed to detectlhe 




porclflII aonoc valve 
Figure C-Jl The concept of rmmurloh,stology staining for IgG 
CJ.3.B(3) Re!lul/s 
C1.3.B.3(1) Porcin.e ao rta valve (ELMAS) 
Blood flow 
• 
FlgU/e C-32 Porcine aorta valve Oeanet sinus and aorto(; wall) stallled WIth ElMAS 
The collagen stallled blue arld the etaston black 
The ELMAS slalll (see Figure C-32) demonstrated that collagen was the rna/Of 
componerlt of the leafiet s extracellular matn~ whereas the elaS\Irl was the maJOf 
extracellular matnx comporlent of POSI-Sirlutubular Jonctlon aortIC wall The Intimal 
,."1111 ....... nf rho> IInrt,,, w",U " !,,,in,," ,"",,!Iv btu" rn< cnit"O"" lind on the IIrtv"rl!,'iAI 
!Iurface !here was a loose anangement of collagen The media mostly showed 
sta,nrng of the elastin fibres throughout With coHagen In between the fibres 
The leaflet sta ined Ilredomlnantlv 101 colagen The flboosa WilS composed of 
def1sely packed collagen wrth some elntlll surrounding the cotlagen The spong'osa 
snowed mostly loosely arrar"\ged collagen WIlhout elashn staining The ventrrcularls 
was also seen 10 be composed of dense collagen WIIh elastin fibres bul w,th a looser 
arrar.gement than that of the frbfosa The COI"Ielatron of the IgG sta,n w,th the 
dlstrrbuiJOn of elastrn and coiagen may ,ndlCate the contnbutron of these IWO major 
constrtuents of the e~tfaceUulal mat"~ to the In"Ifl"IUnogenicrty of the tissue 
C1.l.B.l/ii\ Immunohistology (lOG sta ins) 
Figure C-33 02% Glutaraldehyde fixed porCine aorta stained for IgG uSing the 
Mferent antl·sera A, D, G. J lellnet, B E H, K Sinus, C. F, I L wan, A-C control 
sera D-F· anti ·fresh porcine aortic wal l sera, G-t lIntl·deceliulansed porcme aort ic 
wall sefl.lm j -L anh-porclne plasma flbronectm sera (orig inal magnification lOX) 
The lack of stamlng m tissue exposed to sWine instead of rabbit sera (nol shown) 
confirmed thai sta lrlmg was not an artefact due to the presence of nallve pig 
ImmunoglobulIn 
A Wide range of dilultons (1 50 to 1 20 000) of the labelled IgG was used to 
determme the opt imum concentratIOn fOt IgG staintng to be Sure no background 
Slamlng was seen All the sections were incubated With the same serum d~ul ton 
n 
(1 :100) and stained with the same concentration of labelled IgG (1 :2000) to be able 
to compare the levels of IgG. All the sections stained for the different sera groups 
were done on the same day and the same run to have as little variability between the 
groups as possible. The sections were stained with only the labelled IgG as a 
negative control. All the negative control sections were negative. 
In contrast, there was positive staining for all the serum groups used (see Figure 
C-33). The sera collected from the animals before immunisation had positive 
staining for IgG which made it difficult to compare the different post-immunisation 
sera with each other. The control sera resulted in background staining of the porcine 
aortic valve, suggesting that the animals had preformed antibodies capable of 
recognising epitopes present in the porcine aortic valve protein extract even before 
immunisation. This was not observed in the Western blotting experiments. The 
staining pattern for all the sera were very similar with only some intensity differences. 
The sera of the rabbits immunised against fresh porcine aortic wall tissue showed the 
most intense staining of the leaflet and the sinus area. The sera of the rabbit 
immunised against porcine fibronectin showed the most intense staining of the wall. 
Control rabbit sera 
Leaflet 
There was IgG staining on the edges of the tissue on both the fibrosa and 
ventricularis side of the leaflet. There was some staining associated with the cells on 
the edge of the ventricularis side. There was no IgG positive staining in the 
spongiosa. 
Sinus 
Most of the staining was associated with the loose collagen on the adventitial side of 
the sinus area. There was not staining associated with the cells of the tissue. 
Throughout the media was a light stain that may be staining the extracellular matrix, 
but it was not as intense as the staining of the loose collagen on the edge of the 
adventitial side. The intima had the light staining similar to that of the media. 
The staining of the loose collagen was very intense on the adventitial side (see 
Figure C-33). The staining was not associated with cells, but mostly the extracellular 
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Sera from rabbits immunised with fresh porcine aortic wall tissue 
Leaflet 
The fibrosa and ventricularis stained positive for IgG. The cells on the edge of the 
ventricularis stained positive and close to the edge the extracellular matrix stained 
positive. The spongiosa had a light positive stain of the extracellular matrix, but no 
staining was associated with the cells in the spongiosa. 
The staining was mostly associated with the loose collagen on the edge of the 
adventitial side and the extracellular matrix of the media but not with any cells. The 
cells on the edge of the intima stained positive for IgG. 
Wall 
There was staining on both the adventitial and the intimal side of the wall. The media 
stained lightly positive. The staining was mostly associated with the extracellular 
matrix and not with the cells. 
Sera from rabbits immunised with decellu/arised porcine aortic wall tissue 
Leaflet 
There was no staining in the spongiosa, but the fibrosa and ventricularis both had 
positive staining. The ventricularis had most of the staining and it was associated 
with the cells. 
Sinus 
Only the loose collagen on the adventitial side showed intense staining. The media 
and intima were only lightly stained and which was associated with extracellular 
matrix. 
Both the adventitial and intima had intense positive staining. The media had only 
light staining. 
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Sera from rabbits immunised with fibronectln isolated from pig plasma 
Leaflet 
The fibrosa and ventricularis had positive staining. The staining was associated with 
the cells on the ventricularis side of the leaflet. The spongiosa had light staining 
associated with the extracellular matrix becoming more intense towards the fibrosa 
and ventricularis sides. 
Sinus 
There was some staining of the loose collagen on the adventitial side. Some cells 
stained positive on the intimal side. The media was only lightly stained. 
The adventitia, media and intima showed intense staining of the extracellular matrix. 
The intensity of the staining was the most dramatic for all the wall samples stained 
with post-immunisation sera. 
C1.3.S(4) Summary 
Pre-immunisation sera staining positive suggest that the rabbit had preformed 
antibodies against porcine aortic wall tissue. Thus, the extraction of proteins from 
the porcine aorta wall clearly did not extract all potential antigens as the Westem blot 
did not stain positive with the pre-immunisation sera. In contrast, using 
immunohisotolgy sections of the porcine aorta made it difficult to distinguish between 
preformed antibodies and the antibodies acquired by immunisation. The pre-
immunisation sera stained specifically the porcine aortic wall with less staining 
associated with the leaflet. 
No clear pattem was seen associating IgG with specific distribution of the two major 
constituents, collagen and elastin, of the extracellular matrix. There was a similar 
pattern for all the post-immunisation sera with the blood surface and especially the 
adventitia of the porcine aortic wall presenting potential antigens to target. In all 
groups the most staining was associated with the loose collagen on the adventitial 
surface of the aortic wall. 
The only observation was that the intensity of the stain was different for the post-
immunisation sera groups. The most intense staining of the leaflet and sinus area 
was with the post-immunisation sera from animals immunised with fresh porcine 
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aortic wall tissue and the most intense staining of the aortic wall was with the post-
immunisation sera from the animal immunised with porcine plasma fibronectin. 
Animals immunised with the fresh porcine aortic wall tissue should be exposed to 
most of the possible different immunogens in porcine aortic tissue. Thus, one would 
expect the post-immunisation sera from this group to stain most of the porcine aortic 
wall. Porcine fibronectin (a major constituent of the basement membrane may be a 
major constituent of the extracellular matrix of the porcine aortic wall and thus the 
intense staining of the aortic wall with the post-immunisation sera of the animal 
immunised with porcine plasma fibronectin. Therefore it is clear that even with the 
background staining of preformed antibodies the animals immunised with the porcine 
tissue did acquire antibodies against porcine aortic tissue. 
C1.3.C Specific antigen binding to porcine aortic tissue 
C1.3. C(1) Introduction 
Fibronectin is an immunogen that elicits a significant immune response in 
bioprosthetic porcine aortic tissue. To further investigate fibronectin, the IgG from 
the rabbit immunised against fibronectin was affinity purified and investigated with 
transmission electron microscopy (TEM). The objective was to use immunogold 
labelling to see where the antibody specifically binds in the glutaraldehyde-fixed 
porcine aortic wall tissue. 
C1.3.C(2) Materials and methods 
C1.3.C.2(i) Affinity purification of anti-fibronectin IgG from serum of rabbits 
immunised against porcine fibronectin 
Sera from rabbits immunised against porcine plasma fibronectin was shown by 
western blot to contain moderate titres of specific antibody for fibronectin. Porcine 
fibronectin was used for affinity purification of these antibodies. Porcine fibronectin 
was covalently coupled to a solid medium which was agarose with activated 
cyanogen bromide (Sigma, cat no. C9210). Agarose provide an uncharged 
hydrophilic matrix and cyanogen bromide in basic solution (sodium hydroxide) reacts 
with -OH groups on agarose to form cyanate esters. These groups react readily with 
primary amines under very mild conditions resulting in a covalent coupling of a ligand 
(fibronectin) to the agarose matrix. The porcine fibronectin affinity column was 
prepared (see appendix A 11 c). The rabbit anti-porcine plasma fibronectin antisera 
were pooled and applied to the porcine fibronectin affinity column binding to the 
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porcine fibronectin coupled to the solid medium. This allowed antibodies specifically 
to porcine plasma fibronectin to bind to the column and all rabbit serum proteins, 
including immunglobulins to flow though the column. A low pH buffer {citrate buffer, 
pH 3.0} was used to elute the anti-porcine fibronectin antibody from the column and 
the eluted fractions were immediately adjusted to pH 7.4 to avoid degrading of the 
antibody at the otherwise low pH. 
C1.3.C.2(ii) Transmission electron microscopy: Binding of specific antibodies 
to porcine aortic wall tissue 
The pooled rabbit anti-porcine plasma fibronectin antiserum, rabbit anti-human 
fibronectin immunoglobulin {Sigma, cat no F3648} and affinity purified rabbit anti-
porcine plasma fibronectin were used to study binding of specific antibodies to 
porcine glutaraldehyde-fixed tissue using immuno-gold labelling. The porcine tissue 
was fixed for TEM {see Appendix A22a} and prepared for immune-gold labelling (see 
Appendix A22b). The anti-sera (1:100), the anti-human fibronectin (1:S0) and the 
affinity purified anti-porcine fibronectin antibody {1:10} were applied to the tissue. 
For detection immune-gold labelled goat anti-rabbit immunoglobulin was applied (see 
Appendix A22c). The grids were viewed with TEM. 
C1.3.C(3) Results 
C1.3.C.3(i) Gold labelling (TEM) 
The anti-human fibronectin rabbit antibodies were associated with the elastin and the 
collagen. There was not obvious binding of the antibody to the nuclei of the cells. 
The serum of rabbits immunised with porcine plasma fibronectin was associated with 
most of the porcine aortic wall constituents such as cells, collagen and elastin. 
The affinity purified rabbit anti-porcine plasma fibronectin was mostly associated with 
the extracellular matrix constitutents namely collagen and elastin. There was little 







Figure C-3~ TEM of the gold labelling of the different ant l. fibronechn ,;.nt.bodies wrth 
91u13ra l dehyde-fi~ed porcine aortic wall tissue A-C rabbIt anll-human f.bronechn 0-
F r .. bbn ;mll-porcme f,bronect ln G-t affinity purified rabbll antF-porClne plasma 
tlbronect ll"l A negall~e con1rol wh ich excluded application of a rabbit primary ant i-
sera did nol demonstrate any gold labelling (E - elastin. N - Nuclet, C - collagen) 
C1.3.C(4) Summary 
It IS clear that the rabbits Immumseo WIth porCine plasma fibronecton produced 
antIbOdIeS that recognise porcme aortiC wall tissue It was not c lear how specIfic the 
ant,bodles to fibronectm were because the paltern st,lLoong between the serum and 
the affinity punfied ant,body was srmilar The only dIfference was that there was less 
stamlng of the nuclei lls ing the affinity pUrified antibody The staining seen for 
collagen may be due to libroneCIin associated With collagen. since the labelhng did 
nOl have a highly repetitive distribution thilt one m:ly have expe<:ted If the sera were 
spectfic for co"ilgen itself 
The gold labetllng Iedlnlque confirmed that porCine "ortlC waU tissue was 
ImmunogenIC and the need to identify too specific antigens for masking wOuld help 
WIlh posSIble strateg.es to protect bioprosthetlC tissue against Immune response of 
the host 
Ct .• . Mitigation 01 IgG binding by chemical modificati on of porcine aorta 
lIallles 
Ct .•. A Introduction 
The maskmg of porcine aortIC lIallle tissue fi~ed w~h 02% and 3% glutaraldehyde 
was Investigated The serum Irom rabbds ImrrlJni$ed wrlh fresh porclt'1e tISsue were 
used \0 compare the maskmg of the fresh porC>lle aonlC valve tissue porc ine aMIC 
waU \ISsue fixed with either 0 2% or 3% glutaraldehyde 
Cl.4.B Materials and methods 
C1 .• . B(1} Chemical modification of porcine aortic lIa/II" 
Fresh pomne aortas were collecled from the abattoir (see Appem;h~ A3) The 1Ii1ll1es 
were fixed It'1 10% formalin (fresh tISsue), 02% glutaraldehyde 3% glutaraldehyde 
(see AppendiX All) and processed 11'1 4% paraformaldehVde for Immunohistology 
(see AppendiX A 18) 
C1.4.B(2) Binding o f sent from rabbits Immunised with fresh porcine aortic 
The Immune sera were used to stain the fresh porCIne aortIC lIalve 02% 
glutaraldehyde and 3% g lutaraldehyde fixed porCine ilonlC 1Ii1'ves to COr'lllilre the 
abil~y 01 the different f,xahon concentratIOns of glutarilldehyde to ITIiIsk the ilntrgens 
(see AppendiX A19) Control sera were oblillned from the animals before 
Immunrsat'Orl The serum was applied to the sectIOns at 1 100 dilutIOns," nBS as 
the pflmary ant>body The secondary antlbodv goat anll-,abbn Immu.noglobulln 
conjugated to horseradish peroxidase (Bro·Rad cat no 170-6515) was diluted 1 200 
and applred to cletectthe rabbll IgG Irom the Immune serum bound to the fresh, 0 2% 
and 3% glutaraldehyde had porcme aortic valve respectlvelv 
C1.4.C Resul ts 
• 
Figure C-35 The antr-sera lrom rabbas Immunlsed w,th porcine aortIc wall hSsue was 
used to staIn for IgG on porCIne aortIc valves not fixed fixed wIth 02% and 3% 
glutaraldehyde respecllvely A-C porcine aortic valve not fixed. D-F porc ine aortIc 
valve fixed with 02% glutaraldehyde. G-I porcine aortic valve fixed w,rh 3% 
glutaraldehyde A, 0 G teanet B E. H SInus. C. F. I walt (Onglnal magnifICation 
lOx) 
C1.4.C(1) Fresh pordne aortic valve 
AntJ..whole porcIne aorta IgG stain ing of the fibrosa and the spongiosa layers of the 
leafler were mostly associa ted w,rh the cells The venlnculans stained Intensely 
positive for IgG and the stalnong was associated wrth the cells and the extracel lular 
m"lflx 
There was intense posltrve staintng for IgG in all the layers of the sinus area The 
srainlng was associated WIth the cells and the extracellular malnx 
The aortic wall advent lMI SIde sta,ned Intensely pos<[Ive for IgO The media close to 
the adventitia also stained more than the rest of the media The stamlng in the 
media was mostly associated WIth the extraceUular matrix The Intimal side had less 
slalnlng 
C1.4.C(2) 0.2% glutaraldehyde fixed porcine aorta valve 
The leaflel only had some slall'lll'lg 01'1 the vel'ltriculal'ls sKle of the cells IInmg the 
edge of the vel'ltncularls and the area l'Iext to the vel'l\nculans the extracellular matrix 
sta ined The spongiosa had a light poMlve stain of the extracellular matl'l x but 1'10 
stall'l;l'Ig was associated with the cells 11'1 the spongIOsa 
In the SII'IUS area the stail'lil'lg was mostly aSSOCiated With the loose collagen on the 
edge of the advel'ltJlla l Side al'ld the extracellular matl'lx of the media but 1'10\ WIth al'ly 
cel ls The cells on the edge of the IIlt lma stained posItive for IgG 
There was stalnmg on both the adventrtla l and the Intimal Side of the wall The media 
sta ined light POSlilve The stall'llng was mostly associated WIth the extracellular matrix 
and not WIth any cells 
C1.4.C(3) 3"'" glutaraldehyde fixed porcine aorta vaNe 
The leallet stained only lig htly POSitive A few celis 01'1 the fibrosa stained posItive for 
IgG The spongiosa al'ld vel'ltnculal'ls had no staln'l'Ig associated With cells 
The loose collagen 01'1 the advel'lt l\Ial Side ;1'1 the SII'IUS area stail'led poMlve for IgG 
The extracellular matnx of the media stail'led lightly posit ive. but there was no 
positive staiml'lg 01'1 the intimal Side of the smus area 
The loose collagen on the advenlilial Side of the wal l stained pos~ve lor IgG but 
there was flO sta ining of the media afld ol'lly very light stalnil'lg on the edge of the 
Intimal Sloe of the wall 
C1.4.0 Summary 
Work dOl'le by Zil la et ai ' " ,.. Showed the mftuence of higher glutaraldehyde fi xatIon 
01'1 the calclficatlol'l of bloprosthetoc tissue and thai increasing the glutaraldehyde 
concel'ltratiol'l from 02% to 3% reduced calClficatlol'l 34% 11'1 the sheep model 
Fixat ion of porcine aortic wall With 3% glutaraldehyde resulted In less IgG sl;:l1l'11ng 
bu t the maskol'lg of the \Issue was not compjete The 3% glutaraldehyde trealment IS 
In al'ly case not pract ical because;\ makes the tIssue too tough to use It IS clear that 
addltlol'la l masking IS needed wheo 0.2% glu taraldehyde IS used \0 mitigate the 
mfiammatory respol'lse 10 bloproslhellc heart valves 
C2. Epltope masking by IgG fragments 
C2.t . Confirmation of ti 5$oo specificity 01 sera collected from rabbits 
implantcd with commerc ial bioprosthelic tissuc 
C2.1.A Introduction 
Heart ~al~es are fixed WJth gh.rtaraldehyde to m",sk ",n"gens and protect the ~al~es 
from the Inflammatory response of the recJpoent The hypolhe5l$ thai commerClalJy 
used ii_alive for heart ~alves mask all the an!lgeM 01 the pOfCl11e aortIC tissue was 
.n~esh!ilaled Belgian hares and New Zealand Wh,le 'abblts were Implanted Wllh 
porcine aort iC wall cOt/pons treated wrth dlHerent trellments used commerclil!ly 101" 
SIX wee~s We InvestJgated the humoral Inflammatory response specifically If any 
antlbodiCS were formed dUling the Implanl perIOd speolie 10 porcine aorllC tissue 
C2.1.B Materials and methodS 
C2.1.B(1) Collecting of "bbit serum 
Rabbits were Implanted With coupons treated Wllh commerCial flxall~es and after 42 
days k,lIed under general anaesthesia The serum was colleeted (see AppendIX A I ) 
and stored at ·80·C untd further fractlGnaloOn 
C2.1.B(2) Western biOI detec tion of lissue specific , ntibodies 
POrClf\e aortas wall were collected from the abattOif (see AppenOox AJ) A protelfl 
exlraci were prepared from hornogenlsed porCIne aortIC wall !issue lsee AppendIx 
AS) by overnight extracbQn In a denatunng butter ill 4 C (see Appendi x A7) The 
proleln concentrallon of the extract supernatant was detell1~,ned us'1l9 a detergent 
compatible protem detecllon krt «(DC Protein Assay Bto-Rad) (see Append,x AS)) 
The extract was etectlopl"\orehcaQy separated accOfd'ng to 5r.ze USIng prepafa!l~e 
SDS pajyacrylam>de gradient gel$ (4-20%) (see Appendu A9) The separated 
proteins were transfened 01"110 a PVDF membrane and the membrane was blocked 
overnight In 5% milk pOWder TT8S bolter at 4 C to p.e~en t non-specific binding of 
the detectoon 3flbbody to the PVDF membrane 
A Western blot (see Appendl~ A 10) was performed w~h serum from rabbils 
Impl3flted WIth commerCially fixed porcine bloprosthellc \,ssue as the primary 
antibody diluted I tOO IgG ant,body blnd'll9 10 the porclIle aorta wal l ext ract was 
deteeled w~h secondary anhbody goat anb·rabtlit Immunoglobulin horseradish 
peroxidase COlljugille (8Io-Rad cat no 17()..6515) diluted I 3000 
" 
C2.1.C Results 
C2.1.C(1J Western blot detec tion of tissue specific antibodies 
The Western blot w,th sera from Belga'n Hare and New Zealand White rabb 'l 
Implanted with porcme b,oprosthetic t,ssue usmg prote,ns extracted from porc ine 
aortic wa ll Showed Similar specificity to the tissue 
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Figure C·36 Lane A IS the protem separation of porcine aorta wall tissue extract on 
4·20% 80S PAGE gradient gel under non-redUCing conditions stamed With 
Coomassle Bnlilant Blue R·250 (BIO·Rad, UK) Western blot of porCine aortic wall 
tissue specifiC antibodies In the serum ot animals Implanted with commereiaUy fixed 
porcine aona wa ll after 42 days Blood samples were taken from New Zealand 
INhlle rabbits (lanes 1- 8 ) and Belgian Hares (lanes 9 - 16) before Implant (lane 1 3, 
5.7,9, 11 12 and 15) and after 42 days (lane 2. 4, 6 , 8 , 10 12, 14 and 16) 
C2.1.0 Summary 
Speo:::rflC antibodies form In rabbits Imp/anted With frxed bioprosthetlC !IliWe used lor 
hean valve replacement There were no dlfferen~ between the New Zealand 
WMe rabblls and Belgian hares This made It possible to use sera from both 
speats for further studies 
C2.2. Isolation of tgG ISotype Irom rabbit ser um 
C2.2.A Introduction 
Immunoglobuhn IS the most abundant In circulation and serum IS the usual Starling 
material for lis isolatIOn The serum collected Irom the 51~ New Zealand Whne 
rabbits rnptante(\ WIIh porone aorllC wall coupons treated with dlffererlt treatments 
used commercially was pooled for 19G Isolal lon Three different punfocaloon 
methods were compa.-ed to fond a method that is easy to perform routonely gIVe a 
reasonable yoeld and does notlflachvate or denature the IgG 
C2.2.B Materials and methods 
C2.2.B(f} Dlfferlnl methods of isolating IgG from rabbit sera 
C2.2.B.1(il Protein A affinity chromatography 
Afflnoty chromatography 1$ a me!ilod of separatlflg biochemICal mlx,ures. such as a 
ceil lysate growth medium or blood serum based 00 a highly speclf,c biologic 
In'eractloo such as lhal between antigen and antibody enzyme and substrate or 
recep10r and ligand The specltlc '"teractlon between an "S~uble Ilgana al"lCl SOl \.IDle 
molecule renders the solUble molecule Insoluble and allows ~ to be separated Irom 
soluble contamonants The bonds between the ligand and the molecule can then be 
disrupted to Yield soluble pure molecule The baSIS for ,he punflCallOn ~ the 
SpeaflClly and reversibility 01 the binding 01 soluble molecule \0 II1soluble ligand 
BondIng to the solid phase may be aChieved by column ctvOmii'ograplly whereby the 
solid medium ~ packed onto a chromatography COlumn. the IfIlt'al mixture r\.ln 
through the column '0 allow binding. a wash buffer run through the column to wash 
,he contam1l'lants away and the eluloon buff&!" SUbseqUeotly apploed to the co lumn to 
collect the ptlre molecule 
PrOl(!ln A·5epharose carl be used '0 affinity punfy amobodies from btood serum (see 
Append •• A Ita) PrOle,n A binds 10 the Fe ponlon of the Immunogklhuhn. Protein A 
1$ used as ligand 10 punfy IgG from serum T~e serum IS ano~ '0 bond to the 
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Protem A afflmty malnX and washed from Ihe solid medium Antibodies bond stably 
under physiologICal conditions 01 sak concentratIOn temperature a~ pH, but the 
bonding IS reversible as the bo~s are non-covalent The bound IgO 1$ eluted by 
diS/opting the non·covalent bonds With 0 1 M glyCine Hel (pH 3 00) The 
dISadvantage is that the IgG IS exposed 10 denaturtng CO~ltions Aller exhemes of 
pH have been applied the solutIOn must be neutralised as qUickly as possible and 
then dlalysed Inlo a neulral ISotoniC buffer so as not to permanently denature Ihese 
antlboa~ 
C2.2.B.1(i l) Polyethylene g lycol (pEG) precipi tat ion 
High molecular weight proteinS have been pu"hed by preclprtatoon USing the nonlonlC 
hydrophlhc polymer polyethylene glycol (pEG) 6000 IgG was preelprtated With PEG 
6000 and Isolated by high-speed centrifugation (see Appendix A1 3) Frachonslion of 
plasma proteins wnh 15% PEG 6000 gave a preCIpitate containing mainly IgG a~ a 
supernatant containing maonly atbumln 
The exact mechanism 01 PEG preClp ltalion IS poorly understood It may linked to 
polymers abolny to form Cooled parlOCleS ,n solution and that protei" motecules such lIS 
IgG may diffuse Into the Inter-polymer spaces between PEG molecules and 
precIpitation may occur when they exceed their solubolrty 
C2.2.B.1(j ii) Sodium sulphate 
SOdium sulphate was used as s salt to preclp~ate 10 sediment the anllbod,es from 
sewm (see Append'J( A1 4) The antibodies were removed by centnfugatlon and 
dissolved in PBS 
C2.2.C Results 
C2.2.C{1} Isoi lltion of ra bbit IgG 
C2.2.C.1(1) Protein A "pharose affinity chromatography 
The I~ eluted from the column was I\.In on a 50S PAGE gel to determine d the 
product was pure and Inlac1 The low pH fOf elutIOn fragmented the IgG a~ a low 
Yield of good qua1rty IgO was oblamed by thIS method (see Figure C38) 
" 





Figure C-37 The graph of affinity chromatograp/"e separat ion of rabbit IgG from 
rabb~ serum uSing protem A sepharose afflmty chroma.ography The second peak 
was rabb,llgG eluted with e lulloo buffer 
205 kD-





Figure C-38 The SOS PAGE of IgG isolated uSing prOlem A sepharose affinity 
chromatography lane 1 shows the serum used for Isolating the IgG and lane 2 
shows the IgG erllled from the co lumn 
C2.2.C. 1111) PEG 6000 and Sodium sulphate 
• 29 ~C 
Figure C-39 The IgG ,sola ted b)I u5ll'lg PEG 6000 llane 2) and sodtum sulphate 
llane 3) lane 1 Ihows tne rabbi! serum "om whtch the IgG WilS ,soIated 
PEG 6000 and sodium sulphlle were both "5)' laA methods of -.oIatong IgG The 
PEG 6000 had a h,gher ylt'ld WIIh lesl ffagmenls 
C2.2.0 Summary 
AIle!' C4tIlpanng the three methodl of ISOlatIOn It Will deoded to UR PEG 6000 
method tOf lSoIat,ng IgO It was a qlKk and easy method to UR Ol'lll'lg a goOd 
p-oduct IOf lurthe' use 
" 
C2.3. Digestion o f rabbi t IgG with proteOlytic enzymes 
C2.3.A Introduction 
Three proleolytic enzymes were compared for prepanng Fab or F(ab'), fragmenl 
from rabb it IgG by Pl"OleaSe dlgesllon The following three enzymes were used to 
!iI,ve different antibody fragments Papain cleaves IgG at the amino-terminal Side of 
the disulfide bonds and release the two arms as separate Fab fragments and !he Fe 
fragment Pepsin cleaves In the same general region but on the carbory-termlnal 
side of Ihe d,sulflde bondS giving the F(abJ, fragment where the 1"'10 Illndmg arms 
remain hnked arod the remaining part is cut Into several small fragments Fie,n has 
the abil it y to cleave IgG In either Fab or F(all'): fragment In the presel'lCe of different 
L-cyslelne concentraloons (see Figure C-40) 
F<".~ 
Figure C-40 ProteolytIC enzymes can cleave IgG rOlO Fab or F(ab'): fragments 
C2.3.B Malerials and methods 
C1.3.B(1} Different proteolytic enzymes 
C2.3.B.1(i) Ficin (Fab and F(ab'), f ragments) 
Fic,n IS a thlol protease prepared from fig lalel< w~h a molecular weogh/ of 25 kD II 
has a broad pH wol"l"ng range and cleave IgG ,n Ihe presence of the reducing agenl 
L-c,rstelne at a conceotra\JOIl of I mM on F(ab'), fragments and at a concentration of 
10 mM In Fall fragments The fragments wefe punfied by afm~y chromatography 
(see Appendox AlIa) 
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F,c'n was used wllh bo1h concentration of l-cysleu'\e 10 prepare Fab and Flab'll 
fragmentS (see Appendix A15) Samples were laken al d,ffl!l'f!flt bme Imervals and 
run on a 50S PAGE to determine lhe optimum lime for digesllng IgG wrth F 'Cln 
C2.3.B.l(ii) Pepsin (F(ab'), fragmen ts ) 
Pepsin a member of the PeptIdase A 1 family 15 the predom,"ant dlgestrve prolease 
In the gastroc juice of vertebrates w~h a molecular Weight of 34 kD Peps,n has 
optimal actrvlty wrth nat ive prote ins at appfO~ lfllately pH 1 D. but With some 
denatured prole,"s the ophmal activ ity is at approximately pH 1 5-3 5 Pepsin (see 
Appendi~ A t6) was used In the preparation of F(ab'h fragments Irom an1ibodM!s 
IgG was d'gested With pePSin, which cleaves the heavy chains neal the hinge ,eglon 
One or more of the dlsutnde bonds Ihat join the heavy chains In the hinge regIOn are 
preserved so the two Fab regions of the antibody remain JOined together yM!ldlllg a 
divalent molecule (conlalrllng two ant ibody btndlng S;les). lhe F(ab'h fr agment The 
Ilghl chains remain Inlact and attached to the heaV)' cha,n The Fe fragment IS 
digested IfltO small peptodes The Iragments were pur ified by affinity chromatography 
(see AppendiX A l ia) 
C2.J.B.1{,,,) Papain (Fab fragmenlS) 
Papain IS a cyste.ne protease prepatect from latex from the frUit of ttle papaya tree 
With a molecular weoght of 23 ltD Papam was used 10 cleave antibodoes Into two Fab 
fragments (see AppendiX AI7) . whICh recognIZe the an\Jgen speCIfically With thell" 
vanable regiOll and one Fe fragmenl II cleaves above the hinge regIOn conta,mng 
the disulfide bonds that pon the heavy c;halns but below the Slle 01 the disulfide bond 
between the light chain and heavy eIlam Thl5 generates two separate monovalent 
(comarllng a slng!e antibody binding srte) Fab fragments and an Intact Fc fragmem 
The fragments were purified by aff'My chromatography (see Appendox A 11 a) 
C2.3.B(2) Affinity ehro~t09r~phlc se".r. tion o f .ntibody fr~9ment. 
The Fab o! F(ab'), fragments were separaled from '"tact ..,ndlQested IgG and Fc 
fragments by Pfole," A aff'My chfomatrographv (see Appendix Atla) The mtact 
IgG and Fe flagment DonOS to the protein A and lhe Fab or F(ab'j, fragments are 
waShed through the column because they tack the Fe flagment that IS recognOZed by 
prOleln A. The Fab 0' F(ab'lt fragments were not exposed to the low pH needed to 
elute the tgG t mlhadlons 01 the unbound fragments (Fab and F(ab' ), fragments) 
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were ~ollec!ed The pooled Fab and F(ab'h fragments were dialysed agamst PBS 
(pH 7 " ) 
C2.3.C Results 
C2.3.C(f ) Cleave rabbit IgG with proteolytic enzymes 
C2.3.C.l (i) Fieln 
· 20HO 
·120 ~O 
. 99 ~o 
. ~2 0.0 
·2910.0 
Figure C-41 SOS PAGE of ficin digestion mixture ollgG after hourly ,nlervals with a 
L·cysteme concentration 01 to mM (lane 1 after 1 hour lane 2 after 2 hours. lane 3 
after 6 hours. lane 4 alter 7 hours lane 5 alter 8 hours and lane 6 after 16 hours 
· 109 00 
. '10 . 0 
- 3" 0 
F'gure C-42 SDS PAGE of focln d'gestlon mixture after hourly IIltervals uSlflg a l-
cysteine concentrat ion of 1 mM (tane 1 before startillg lane 2 after 1 hour lane 3 
after 2 hours , lane 4 after 6 hours" lane 5 after 7 hours lane 7 after 8 hours and lane 
8 after 16 hours 
Ficin digestion after 3 hours with L-cyslelfle concentration of 10 11M was the 
opt,mum condit'on with a good yie ld of Fab andlor F(ab"h fragments 
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Figure C-43 Affinity ct!I'omalDgl'ilp/W; 5eO<IratlOn of fragments from tilbblt IgG 
digested WIlh fICin uSIOQ prolelt\ A-sepharose ColUflVl Tile fIrst peak IS Fab an(l(or 
F(ab h fragments 
C 2.3.C.1 (ii) Pepsin iI nd Papain 
Fogur. C,",,4 50S PAGE of the dofferenl prOleolyt lC enzyme digests of rabbit IgG 
Extl group shows In Ihe tirll lane the IgO doalyHd agamst Ihe buHer used and the 
" 
second lane the dlgesllon n1IXture lane 1 and 2 shows Ficin dlgesllon afler 8 hours, 
lane 3 and 4 dl9eslJon WIlh papain and lane Sand 6 dlgesllon With pepSin (pH 4 S) 
C2.3, O Summary 
II was decided to use FICin digestion because It was reliable and had a good Yield of 
Fab andlor F(ab-b fragmenls afll!!' only 3 hOllis The conch\lons for dlgeshon were 
not as harsh as WIth pepson (pH 4 S) II was also an att ractive option because II was 
possible to get !!flhet' Fab or F(ab'), fragments USing the same enzyme and It was 
poSsible to evaluate both h-agments as potential masking agenls 
C2.4. Mask porcine aortic wall with IgG fragments 
C2.4.A Inlroduction 
II IS essenllalthat the immunoglobulin fragments are SuffICient to mask the extent of 
ep1topes e~posed In the trssue which are capable of binding host anubody 
Immunoh,sto1oglCal staining WlU allow a VISual conflllTlalion of the quenching effect of 
Fab or F(ab'h fragments appllcatron 10 pOfClne aortIC wall tISsue CompanIon of 
masked VI!!'SlI$ non-masked skdes with subsequent appllCallon of .ntact peroxidase 
conjugated IgG Will prOVIde conhdence IIIaI Ihe appi«:atlon of Fab Ot F(ab'h 
fragments are etfecuve In maskmg Immunogenic eprl opes 
C2.4.S Materials and Methods 
C2.4.B(I) Conjugate peroxidase to IgG 
IgG isolated from rabbit sera was labelled with horseradISh perOXidase (see 
Append ix A18) PerOXidase produced by horseradIsh root IS a stable highly <!CINe 
enzyme Conjugation fs achieved usmg glutaraldehyde to cross·hnk Immunoglobulin 
to Ihe enzyme 
C2.4.B(2) Binding of IgG fragments to porcine aorta wall 
Immunohistological staining wil l allow a VISual confirmation of the quenehll'\g effect of 
Fab or F(ab h apphcaton to porcine aorta t'Slue A~hough the eoncemrallon of Fab 
01 F(ab')1 witt be far in excess when applied 10 a histological slide, companson of 
masked versus non· masked s~des w~h subsequent appbcallon ofliibetled mtact IgG 
Will pro~ide confidence thai the applicat'on of Fab or Flab'h is effe<:hve 3t masklfl9 
Immunogenic 8"pllopes 
POfClne aona wall was CIA ,nlO 12mm coupons and fixed in 0 2% glutaraldehyde (see 
AppendIx AI2). The coupons we/e prepared for ,mmunotustology (see Apendix A 19). 
Fab fragments _<8 used to mask the epllopes as pnmary The peroxIdase_ 
conjugated IgG was used as the secondary and detectlO!1 antIbody For the control 
grotJp, the incubatIOn WIth Fab fragmen ts was excluded The peroxidase conjugates 






Ftgule C-45 The masltlflg of ep~opes Wtlh Fab fragments 
'" 
C2,4.C Results 
C2.4.C(1) Binding of IgG frllgments to porcine 1I0rfa willi 
Figure C-46 0 2% glutaraldehyde fixed porc'ne aonlC wall sections staoned with 
conjugated rabb't antJ porc ine IgG-HRP 
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Figure C-47 02% glutillaldehyde filed porcine aortic wan sections were fIrStly 
masked with Fab and F(ab'h fragmMtS plepared with ficin digestIOn of rabbit tgG 
After masking the sections wele stained with CO!llugated rabbit ant. porCine IgG-
HRP 
The Fab and F(ab)2 fragments prepared with licin digestion of rabbit IgG prevented 
staining of the sectIOns with conlugated rabbit ant i porcine IgG-HRP (see Figure 
C-47) Only a few celts stained posrtlve for the IgG 
'" 
C2 .• . C(3) Pepsin 




Figure C-48 a 2% glutara ldehyde fixed porcine aortiC wal sectIOns were first!} 
masked w.th F(ab")) fragments p.epared WlIh pepSUl d'9~hon of rabbtt IgG Aller 
masking the sections were stained wrth conJUgated rabbrt anti porc:lle IgG-HRP 
The Fab and F(ab·h fragments prepared w~h pepsin digestIOn of rabbit IgG 
prevented sta lnong of the sectIOns wl !h COn)ug,l!ed rabb.t ant. po,clIle IgG-HRP (see 








Figure C-49 0.2% glutaraldehyde fixed porCine aon,c wa ll sect ions were fi'lOtly 
masked wrth Fab antibody fragments prepared with papain digestion of rabbit IgG 
After masking the seeMns were stained WIlh conjugated rabb it anI! porcine IgG-
HRP 
The Fab and F(ab' ), fragments prepared with papain dlgesllon of rabM IgG 
pre~ented staining of the sections with conjugated rabbit anti porcme IgG-HRP (see 
Figure C-4g) Only a few cells stamed positive for the IgG 
C2.4.D Summary 
Sera from ammals Implanted wrth porcme aonlc tissue showed specificity for porcme 
aon,c tissue The sera from these animals were taken and the IgG Isolated The IgG 
Fc fragment was removed by proteolyt ic digest ion to produce Fab andlor F(ab'), 
fragments Intact IgG from the post· ,mplant sera were labelled wrth horseradish 
pero~idase to be used to label the antigens present on the Immunohistology sect ions 
of porc ine aon,c wal l The opt ion to use commerc ially available prote in G conjugated 
to horserad ish peroxidaSe was not a~allable because protein G bmdS to Fc fragment 
and Fab fragment of the ant ibody111 
'" 
The concept is that the Fab and/or F(ab')2 fragments would bind to the tissue first 
and block all the possible sites for the intact labelled IgG to bind. Applying either Fab 
and/or F(ab'h fragments to the porcine aortic tissue before applying the same sera 
from which the fragments were prepared, masked the porcine aortic tissue 
sufficiently to mitigate binding of the antibodies present in the sera. Therefore 
applying these fragments to porcine heart valve tissue before implanting it into an 
animal (or patient) has the potential to mask the antigens from antibodies binding. 
The removal of the Fc fragment from these fragments may prevent inflammatory 
cells with Fc receptors from binding to the tissue. 
O. In Vivo Pilot Study to assess the anti-inflammatory efficacy of porcine 
bioprosthetic tissue masked with specific immunoglobulin fragments 
01. Introduction 
Although the goal of this thesis was to provide in vitro proof of principle supporting 
the concept of immunoglobulin fragment masking of residual immunogen in 
contemporary bioprosthetic heart valves, a pilot in vivo study was nevertheless 
performed to identify potential, and to some extent, anticipated obstacles which might 
otherwise limit the successful implementation of this novel technique. In no means 
does this aspect of the work represent a definitive assessment of the success or 
otherwise of this technique. 
Some anticipated problems relate to the anticipated variation in immunogenicity of 
the epitopes contained in the tissue and therefore the resulting avidity, masking 
potential and titre of the immunoglobulin fragments thus produced. 
Aspects that have not been addressed here but which would also be important in the 
translation of this concept to the clinical arena include whether the use of 'xeno-
immunoglobulin', that is which is produced in animals, would be appropriate or even 
desired. The concept of glutaraldehyde tethering of immunoglobulin fragments by 
fixation subsequent to their application, a process that is anyway necessitated in the 
production of bioprosthetic heart valves, is a convenient starting point as it ensures 
that bound immunoglobulin fragments, especially low avidity ones, are not lost from 
the tissue after implantation but may also hold the key to minimizing a host response 
to these foreign molecules themselves. Certainly, there are precedents for the use of 
xeno-antibodies in humans, including the widespread use of polyclonal rabbit anti-
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thymocyte globulin (Fresenius) and mouse monoclonal anti-T3 (OKT3, Orthokline) in 
transplant patients, without an ensuing anaphylactic response. 
02. Materials and Methods 
02.1. Study design 
New Zealand White rabbits were immunised with homogenates of porcine aortic wall 
tissue (4 animals). Immunoglobulin G was isolated from the serum of the immunised 
animals and used to treat porcine aortic wall tissue as well as decellularized porcine 
aortic wall tissue. Coupons punched from treated aortas were implanted subdermally 
into New Zealand White rabbits (6 animals) to compare the inflammatory response of 
Fab masked versus unmasked control groups. 
02.2~ Immunisation 
Preparation of tissue for immunisation 
Fresh porcine aortas were collected in cold PBS (pH 7.4) at the local abattoir 
(Maitland, Cape Town) from normal, healthy pigs. They were cleaned and rinsed in 
PBS (pH 7.4). The porcine aortic wall was cut into smaller pieces and frozen in liquid 
nitrogen. 
Homogenisation of tissue 
A stainless steel vial and associated ball bearings, as well as a mortar, pestle and 
spatula, were first cleaned with 70% ethanol and cooled in liquid nitrogen. The 
frozen aortic wall samples were placed in the cooled stainless steel vial together with 
the ball bearings and homogenized for a few seconds. After all the aortic samples 
were roughly homogenized they were placed in the cooled mortar and frozen with 
liquid nitrogen and ground with the pestle to form a homogeneous mixture. The 
resulting powder was frozen in liquid nitrogen, freeze-dried overnight and then stored 
at -80D C. 
Preparing of homogenates for immunisation 
Sterile saline (0.5 ml) was added to porcine aorta homogenate (10 mg) and the 
mixture vortexed to suspend the powder. Freund's incomplete adjuvant was added to 
the saline mixture in a 1: 1 ratio and mixed by passing the solution through two 
connected syringes to emulsify the immunogen. 
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Immunisation of the animals 
Female New Zealand White rabbits were used for immunisation. Four animals were 
immunised using porcine aorta homogenate. The emulsions were injected 
subcutaneously bilaterally (0.5 ml at each site) on the animals back with a total dose 
of 10mg tissue. After 14 and 21 days the animals were each administered a booster 
immunisation of the same dose. Test blood was drawn immediately prior to 
immunisation and immediately prior to booster immunisation to monitor antibody 
production. Animals were killed under anaesthesia after four weeks. A maximum 
amount of blood was collected by cardiac puncture into uncoated Vacutainer™ glass 
tubes. 
Isolation of serum from rabbit blood 
The blood was allowed to clot at room temperature and centrifuged at 1260 xg for 45 
minutes at 4 DC. The serum was collected and stored at -80DC. 
D2.2.A Western blot detection of tissue specific antibodies 
A protein extract was prepared from homogenized porcine aortic wall tissue by 
overnight extraction in a denaturing buffer (50 mM Tris, 0.1% SOS, pH 7.4) at 4DC. 
The extract was separated by SOS polyacrylamide gradient (4-20%) gel 
electrophoresis. 
The separated protein bands were transferred onto PVOF membranes using a semi-
dry electro blotter (Biorad) after equilibration in Towbin transfer buffer (25 mM Tris, 
192 mM glycine, 20% Methanol, 0.1 % SOS, pH 8.3). The membrane was blocked 
overnight in 5% (w/v) milk powder (fat free) in Tween-Tris buffered saline (nBS) 
(0.05% Tween-20 in 20 mM Tris-HCI, 500 mM sodium chloride, pH 7.5) overnight at 
4 DC. Sera collected from immunised rabbits were applied as 1: 1 00 dilutions in 5% 
milk powder solution for 90 minutes at 37DC using a multiscreen device (Biorad). 
After TrBS washing, specific IgG antibody was detected by use of a goat anti-rabbit 
immunoglobulin horseradish peroxidase conjugate (Biorad) secondary antibody 
diluted in nBS and applied for 60 minutes at 37DC. After the final nBS wash, 
development of bound complex was performed using an Opti-4CN™ Substrate kit 
(Biorad). 
107 
02.3. IgG fragment preparation 
02.3.A Isolation of IgG from rabbit serum 
Two serum volumes of 0.01 M borate buffer, pH 8.6, were added to rabbit serum. 
Pulverized PEG (Mr 6000) was added to the mixture to give a final concentration of 
15% (w/v). Once the PEG was dissolved the mixture was centrifuged at 12100 x g 
for 10 minutes at 4°C. The pellet was dissolved in two serum volumes of borate 
buffer, pH 8.6. Pulverized PEG was added to give a final concentration of 15% (w/v) 
and once dissolved the mixture was centrifuged at 12100 x g for 10 minutes at 4°C. 
The pellet was dissolved in half the original serum volume PBS (pH 7.4), containing 
0.05% sodium azide and stored at 4°C. 
02.3.8 Preparation of Fab fragments 
IgG was dialysed against 50 mM Tris, 2 mM EOTA, pH 7.0. Ficin (Sigma) was 
added at a ratio of 1 :30 (E/S) to IgG and activated by adding L-cysteine to a final 
concentration of 1 mM. The mixture was incubated at 37°C under gentle shaking 
and after 3 hours the reaction was ended by adding 1: 1 0 (v/v) of a 100 mM N-ethyl-
maleimide solution. The mixture was dialysed against PBS (pH 7.4). 
02.3.C Affinity chromatographic separation of antibody fragments 
Protein A-Sepharose (Sigma) was re-suspended in 0.05 M sodium phosphate, 0.15 
M sodium chloride, 0.005 M tri-sodium citrate, pH 7.4 (equilibration buffer). The 
suspension was degassed and packed in a column (1 cm x 10 cm) under gravity. 
Using a protein A-sepharose low-pressure affinity chromatography column 
equilibrated at room temperature with a flow rate of 0.5 ml/min, the Ficin digestion 
mixture was applied and residual intact immunoglobulin separated from unbound 
immunoglobulin fragments. The eluate was monitored at a wavelength of 280 nm 
and samples (1 ml) collected in an automated fraction collector. Bound IgG was 
eluted with elution buffer (pH 3.0) between runs. Fab fragments were pooled and 
exhaustively dialysed against PBS (pH 7.4). 
02.3.0 SDS PAGE confirmation of Fab fragments 
The pooled Fab fragments were diluted 1:4 with non-reducing protein loading sample 
buffer (Biorad) and loaded on a 4-20% gradient SOS-polyacrylamide gel. SOS-
PAGE was performed according to Laemmli. The proteins were stained with 
Coomassie Brilliant Blue R-250 (Biorad). 
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02.4. Rabbit implants 
02.4.A Tissue preparation 
Fresh porcine aorta walls were collected in cold PBS with 0.05% sodium azide (pH 
7.4) at the local abattoir (Maitland, Cape Town). After rinsing in PBS the samples 
were transferred into cold PBS with 0.05% sodium azide (pH 7.4). 
Decellularised porcine aortic wall tissue was prepared by Medtronic Inc. (Heart Valve 
Division, Santa Ana, CA, USA). 
Circular coupons (12mm) were punched from the post-sinotubular ridge of porcine 
aortic wall from either fresh or decellularised porcine aortic wall tissue and 
immediately prepared according to their respective treatments. 
Group 1: Porcine aortic wall treated with 0.2% glutaraldehyde 
The coupons were transferred to HBS (pH 7.4) for 48 hours at 4°C before transferred 
to cold 0.2% glutaraldehyde in PBS (pH 7.4) After 7 days fixation at 4°C the samples 
were washed in high-volume HBS (with sodium azide. 4 x volume of fixative, 4°C) 
and stored in low-volume sterile filtered HBS (without sodium azide, 4°C). 
Group 2: Decellularised porcine aortic wall treated with 0.2% glutaraldehyde 
After 7 days of HBS washing the coupons were transferred to cold 0.2% 
glutaraldehyde in PBS (pH 7.4) for 7 days at 4°C. After fixation the samples were 
washed in hjgh-volume HBS (with sodium azide. 4 x volume of fixative, 4°C) and 
stored in low-volume sterile filtered HBS (without sodium azide, 4°C). 
Group 3: Porcine aortic wall with Fab fraaments and treated with 0.2% 
glutaraldehyde 
The coupons were transferred to sterile filtered Fab fragments in HBS (pH 7.4) for 48 
hours at 4°C before transferred to cold 0.2% glutaraldehyde in PBS (pH 7.4) for 7 
days at 4°C. After fixation the samples were washed in high-volume HBS (with 
sodium azide. 4 x volume of fixative, 4°C) and stored in low-volume sterile filtered 
HBS (without sodium azide, 4°C). 
Group 4: Decellularised porcine aortic wall masked with Fab fragments and 
treated with 0.2% glutaraldehyde 
After 7 days of HBS washing the coupons were transferred to sterile filtered fab 
fragments in HBS (pH 7.4) for 48 hours at 4°C before transferred to cold 0.2% 
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glutaraldehyde 10 PBS (pH 7 4) for 7 days at 4"C Alter fixation Ihe sample5 were 
washed rn hIgh_volume HBS (wIth sodIum aZIde 4 x volume of',xatrve 4 "C) and 
sloredlO low-volume sterile l Ittered HBS (WIthout sodium aZIde 4'C) 
Pnor to ImplantatIOn. coupons were thoroughly rinsed by washIng for two mlOutes In 
each of three basrns conlalnlng sterIle filtered HBS wIthOut sodIum azide After 
washing the Coupons were kept in sterIle filtered HBS wrthout sodIum azide (4 "C) 
unllllmplantalion 
02.4.B R"bb/r SlJbdermal /mplllnl modlf/ 
Samples were implanted subdermally IOta pouches created by blunt dissecllon 
benealh the faSCIa on the Dack of anaesthetllled New Zealand 'htl,te rabbits AortIC 
wall coupons were onenlated wllh the adventlllal surface facrng towards the sk,n and 
theIr ablumenalsurface towards the skeletal muscle After six weeks of l~antatJon 
the animals were kdled and the Implants retneved by en bloc removal of ttle skon from 
the bilck of the anlfr",1 WIth the coupons 51111 »dne"ng an<! encased III theor f,brous 
capsules The skin was Immersed In 4'l1o paralormaldehycle so/utlOn and stored 
overnIght ,11 4 C 
02,5. Histological processing of coupOns 
FolloWIng overnIght fixation the coupons WIth the SUfroun(llfl9 muscle and sklO were 
Cut from the Skin for hIStOlogy and Immunotustocllerl1lStlY (flgUfe I· I). The samples 
were cut 1010 two lIa~es tongrtudlnatly further processed emoedded In wa~ anc! cui 
Into sectIons The sectIOns were stained wl\h haem3toxyhn and countBfSlalned wl\h 
eOSIn 
Figure 0-1 Skin nap after en bloc removal and parafarmaldehyde fixation With 
adherIng aortIC wah coupons pilar to sectIOnIng This method SBiVe(! to presel'lle the 
otherwISe fragIle adherent inl'lammalory nm anc! fibrous capsule 
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02.6. Analysis o f coupons 
Histological examlnallOn of tile stained sections was perlormed on a Eclipse 2000 
light microscope (Nikon) 
03. Results 
03.1 . Immunisation Response 
An acquired immune response to the porCine IIssue homogenates used to Immunize 
New Zealand White rabbits was observed In each of the four animals (Figure 1-2) 
Although the Identity of the r ndi~ldual bands was not determined. as rt fell beyond the 
scope of th iS theSIS. and may also represent different fragments of similar ant igen In 
cases an apparently shong broad spectrum response was eVident With the bulk of 
Immunoglobulin being specmc for proteins ranging in SIZe from as hogh as 500 kO to 
19 kO 
w 
Figure 0·2 Western blot shOWing tissue-speCific antibody In serum from immunlsed 
New Zealand White rabbrts l anes 1 3, 5 and 7 correspond to pre-immunisation sera 
from the lour immunlsed anrmals and lanes 2. 4. 6 and 8 correspond to the 
corresponding pre-te rmination. that IS post-boost sera 
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03.2. Histology 
One of the ove~lghts Identl1ied In thIs study was the Slmu~aneous ImplantalJOn of aU 
the defIned groups In each of the recIpient anImals Ordmanly, thIS method IS 
practIsed when screenIng the catcihcClMn potentJi~1 of blop!"oSlnetre treatments In ral 
subdermal models and indeed thIS has not adversely affected analYSIS of 
glutaraldehyde treatments in terms of ttlell InflammatIon potential as the response IS 
always Irmrted 10 a small envrronment adjacent to the Implant $jte Naturally. i, IS 
accepted thaI tl1e '&sponse to one sample can carry over to another through the 
acbO<l 01 Iympllolunes and pro-inflammatory stimuli such 115 complement factors 
However ft was rather tn!'! qualullve nalure of the response rather than Its 
quanlllallve magnItude that we WIShed \0 e~a/lllne here 
It IS rmponant to note thai valves unptanted clinically lypocaHy undergo ...,flammatlon 
predominantly on the ablumenal surface Indeed 11 IS a fallacy thaI. at least In Ine 
case of no ..... vrtat tISSue valves the rnllammalory response is blood borne ThIS IS 
partly due 10 Ihe shear stress expenenced by the lumrnal surface. especIally In the 
high Row aonlC POSLtlon AdmIttedly transanastomobC hYPl'!fpi.aSla does Indeed 
enerosen along the blood surface from the anastomoses. both upstream and 
downstream, where smooth muscle f<om the medIa of the Inlured natIve vessel IS 
abte to cross me now severed internal elastIC lamella and progress along the surface 
of Ine prostheSIS Frequl'!f1tly thiS allows a layer of inflammatory cells moslly 
macrophages and foreign body gIant cells. as well as mlerothrombi, to persISt 
between thIS hyperplastIC tIssue and the prosthesIS rtsell The resu illng 'pannus· can 
lead to sten05lS 01 the valve as 1\ extends over Ihe leaflet cusps and IS often the site 
of extntlSlC calcrflCahon In lhe subdermal Implant model howevl!f . thIS phenomenon 
IS lor obvIOUS reasons flOC observed Nevenheiess although the shear stress 
scenano IS absent irlthls posrtlOn tne Inhmal (Iumnal) surface IS tess suscaplible to 
inflammation and. for reasons gIven above "IS appropnate to evaluate the response 
to the adventrt.al (ablumenal) s,de Instead 
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Group 1: Porcine aortic wall treale-t:/ wilh 0_2% glutara ldehyde 
Here two paltllfns of InflammatIOn are obsel'\led (Fig lire D-6) In (a)_ a large number 
of foreign body giant cells (F6GC) interspersed W11h granulocytes both poIymOJpto 
naulroph,ls (PMN) and eoSlnophlls (EOS) but without lymphocytes (Ly) or plasma 
cells In (b). PMN and EOS predominated wah fewer F6GC and scanty Ly 
GCQup 2: Qecellularised porcine aortic wall treated with 0.2% glutaraldehvde 
In tl'le GA treated decellulansed tissue (Figure 0-7), granulocyte pl"edomlnance 
simolar to that seen In the non-decellularised tissue (Group 1) was agam evident w,th 
equal ratIOS of PMN and EOS In both (a) and (b) Macrophages (Mo) wefe seen In 
(b) and In contrast to GA fixed non---<jecellulansed tlSSlJe (GrOlJP 1)_ no Ly were 
detected II III wortl'l nOlll1g Ihat. when decelllJlarised tissue was not croU-linkad a 
slarde granulocyte pus has often observed conSist ing of apoplosed PMN and 
pl"e5umably EOS The e~tent of PMN and EOS In Ihis group of GA fl~ed 
cMce8uJarised \Issue dod not conSll1l.rte pus whICh IS lJwally seen as closely packed 
caD remnant areas W11h dear fisslJres extendmg throughout 
Groue J : Porcine aartic wall wi lh Fab 'ragments and truted wi th 0,2% 
qlula" ldfllhyde 
The resutts of Fab maskltog followed by GA lethenng (Fogure 0-8) did not show imy 
clear differences compared to non· masked bsslJe F6GC were pl"esel1t If'I large 
numbers as was !he tYPIcal PMNlEOS glanlJlocyle response In (e) a~en a few Mo 
were observed as wei as scanty Ly In (b). a nlJmbet of plasma caWs were seen 
clearly suggeslf/lg IIlat a humoral response was st~1 actnIe 
Group 4: Decellularised porcine aorth~' wall muked with Fab 'ragm.nts end 
Ireared with O.~Ai glutaraldehyde 
The response In the decellulansed, Fab-mas«ed GA llJ.e<I tls'lJe (FiglJre 0 ·9) was 
again Similar to thai observed In the olher groups However substantially fewer 
F6GC were observed· they were completely absent on (b) - and Mo were also 
completely absenl PMN and EOS were the predommanl cell type 01 essenllally a 
granulocytic, " not fo reign body, response In (a), a few ptasma cells wefe 
never!heless noted and on (b) the granlJlocyte response had developed fllO the 




Figure 0-3 Two replocates demonstratmg Ihe Inflammatory nm associated 'Mlh the 
acNentilial surface 01 0 2% GA fuced oorelflB aortic tiSSue. The medIa can be seen in 
Ihe upper right 
, 
• .,' 
F'gtKe D-4 Two repllca:es oemonstratlng the inflammatory rim associated Wllh the 
adventrt~1 surface of decell"lansed and subsequently 0 2% GA fixed porClIle aonic 
tISSue The media de .. old of smooth muscle cejls can be seen 111 the upper fight 
~~, 
I' , • . ' b 
Frgure 0-5 Two replicates demonstrating the mnammatory nm assOCIated WIlli the 
advenlJl. ... t striaee of Fab masked and 0.2% GA fixed porcone aoruc !ISsue 
'" 
• . .. • 
• • 
Figure 0-6 Two replicates demonstrilling the Inflammatory nm asSOCIated wl!h the 
actvent~lal surface of fab masked deceUularlSed and subsequently 02% GA fixed 
porcine aortic IIS5ue 
04. Summary 
Although 1M concept of UI~I$lng Immunoglobulin produ<:ed In rllSpOnse to 
Immunogens which fixatIOn Ifealments such as GA cross-linking. are ,ncapable of 
modifying or maskmg app8i1fs to hypoltlellealty be a logical strategy al first glance 
ThiS was indeed confirmed by the "' VItro aspect of th,s study It is clear from th,s 
pdot m VIVO study that the U$8 of mmunoglobuln fragments needs to be optimised \0 
be of any value 
Part of the problem IS likely due to the fact that the tiSSue Itself is a heterogenous mix 
of proteins and prOleoglycans whoc;h are capable of sensrtlsong the host ImmUrle 
system on a dose-dependent manner Some of these potential immunogen' may be 
sufflCMffilly hodden deep In the Intenor of the aon,c wall or alternatively, resu~ In 
Immunoglobulins WIth low avidIty whereas othelll, whIch may be preval8!1t In only 
small quanlJl.es, may be much more accesSIble or result In high avrd~y antIbody 1115 
lIkely therefore that a cocktail of indIvIdually optimISed anllbody clones WIth defined 
SpeafiClty and whIch WIll also result In total masking of their respectIVe largets 's 
what WIll be requlfed 
Another part of tile problem IS Ihe very nalure of Ihe ImmuneJrnflammatory response 
Itself and whIch has much redundancy burll In SImply blocking one "spec! thereof 
may not prevent another from respondrng Complement. for example acts through 
both antibody dependem and antIbody rndependent pathways, Innanvn"tory cells 
such as milCfophages and neutrophlls have, In a<idl\JOn to thell Fc rll(;eptofS 
complement receptors which may be more effective at initiating a process of 
phagocytosis or, more likely with respect to highly cross-linked bioprosthetic tissue, a 
process of 'frustrated' phagocytosis. 
Even the nature of the complement cascade itself introduces soluble proinflammatory 
factors which may thwart any attempt directed solely at inhibiting immunoglobulin 
binding in the quest to mitigate inflammatory demise of a valve bioprosthesis. 
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E. Discussion 
Bioprosthetic heart valves have a limited average lifespan of 10 years191-194 and 
patients younger than 60 years will likely need more than one redo operation in their 
lifetime. Therefore improvement of bioprosthetic heart valve durability is urgently 
needed. In this study the feasibility of using Fab fragments to quench inflammation 
of heart valve tissue through antigen masking was evaluated. This concept relies on 
additionally utilising the standard glutaraldehyde fixation process used in the 
manufacture of bioprosthetic heart valves in order to tether immunoglobulin 
fragments to the tissue prior to implant. Removal of the Fc fragment has the 
potential to prevent adherence of phagocytes and complement to the graft. Enzyme 
digestion of the immunoglobulin molecule potentially results in either Fab or F(ab'h 
fragments, however, the monovalent Fab fragments are smaller and hypothesized to 
penetrate the tissue deeper. The larger F(ab'h fragments have the potential to bind 
to more than one of their epitope targets and therefore with greater avidity to the 
antigen. Therefore, antibody fragments produced in rabbits immunised with different 
porcine heart valve tissue preparations were used to mask tissue representative of 
that seen in contemporary heart valve bioprostheses. Proof of concept was sought 
based on the potential for these fragments to mask histological sections in vitro and 
indeed clearty demonstrated high efficiency of masking against the binding of intact 
immunoglobulin to the tissue. To investigate whether this masking was capable of 
altering the inflammatory response in vivo, a pilot study was performed in a rabbit 
subdermal implant model. Here, in addition to evaluating the response to 
glutaraldehyde fixed porcine aortic wall tissue we also examined whether the method 
had potential with respect to decellularised aortic wall tissue where the antigen load 
was perhaps limited to largely extracellular matrix components. Both tissue groups 
were treated with antibody fragments tethered onto the tissue to avoid issues of 
premature release of these immunoglobulin caps. Although there was no clear 
difference observed between masked and control groups there was a hint that some 
mitigation of foreign body giant cell formation had resulted in the case of the 
decellularised tissue. 
Faustman and Coe 212 first illustrated immunoprotection of xenografts using F(ab'h 
fragments to mask the donor major histocompatibility complex class I (MHC-1). 
Rejection of transplanted xenogeneic human pancreatic islets and liver in the mouse 
was circumvented by masking donor MHC-1 or tissue-specific epitopes with F(ab'h 
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antibody fragments. This strategy eliminated the need for recipient 
immunosuppression and allowed islet xenograft survival beyond 200 days. This 
strategy was later applied for immunoprotection of neural xenografts by Pakzaban et 
al213 who used monoclonal antibody F(ab')2 fragments specific to porcine MHC-1 in 
an attempt to mask this complex on porcine fetal striatal cells transplanted into rat 
striata. The fragments enhanced survival of the xenografts Significantly compared to 
non-immunosuppressed controls and thus were shown to have the potential for 
immunoprotection of neural xenografts. 
In contrast, our study strove to mask not just one or two, but all potential residual 
immunogens in the highly complex bioprosthetic tissue in order to mitigate the host 
inflammatory response. Schussler et al214 compared intravenous immunoglobulin 
(lVlg) (polyclonal human IgG prepared from pools of plasma from several thousand 
healthy blood donors) with F(ab'h fragments thereof with respect to the ability to 
minimize the response to bioprosthetic porcine heart valve tissue in a subcutaneous 
rat model. The treatment reportedly reduced the antigenicity as well as reduced the 
cellular response to the glutaraldehyde-fixed valves. Our study used serum from 
rabbits immunised with porcine aortic wall based preparations to achieve higher titres 
of antibodies directed against porcine heart valve tissue. In contrast, our study 
utlilised allogeneic immunoglobulin to prevent a xenogeneic response to the antibody 
fragments themselves. Immunoglobulin fragments were used based on the premise 
that this would prevent adherence of phagocytes via their Fc receptors. 
A limitation of the study was that, except in the case of porcine fibronectin, most of 
the antigens targeted were unknown. An approach similar to the immunoproteomic 
identification of xenoantigens in bovine pericardium done by Griffiths group 215 should 
ideally also be performed for porcine bioprosthetic heart valve tissue. Their group 
identified thirty-one putative protein antigens which included cellular and matrix 
proteins. 
We realised the importance of masking not just one but multiple xenoantigens. 
possibly with more than one epitope being targeted for each antigen. The 
consequence of immunising animals using a crude extract of porcine tissue is limited 
in that the response is dictated by the availability of antigen in the tissue. This clearly 
represents an imprecise approach but nevertheless provided an important insight in 
this early proof-of-concept phase. Future work should identify a library of highly 
immunogenic proteins present in bioprosthetic heart valve tissue and tailor a cocktail 
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of poly- or monoclonal antibody fragments to a selected number that would still 
achieve the desired effect. 
The inflammatory response is a complicated network of responses triggered by a 
variety of molecules and it would be naIve to suggest that masking antigens with Fab 
and/or F(ab')2 fragments would be sufficient to mitigate the response. Analysis of the 
response of our work and others clear1y showed that the response to bioprosthetic 
heart valve tissue is largely a xenogenic response dominated by macrophages, 
neutrophils and foreign body giant cells. A large part of the research done in the 
bioprosthetic heart valve field is done using the subdermal rat model. It is a well-
known fact, although mostly ignored, that in the rat model, inflammation is 
predominantly a lymphocyte response. Initially the response includes neutrophils 
and macrophages but the response quickly gives way to a mainly lymphocyte 
dominated one. In the primate as well as the rabbit, unlike the rat, a macrophage 
focussed response predominates and is thus a more representative model to use. 
Neutrophils, macro phages and foreign body giant cells all have Fc receptors that 
recognise and wjll bind to the Fc fragment of IgG opsonised tissue. Fc receptors 
recognise specifically the Fc portion of the immunoglobulin molecule. This binding 
property of IgG antibodies has been shown to be independent of the Fab region of 
the antibody and requires only Fc interactions216. When binding to Fc receptors, 
antibodies effectively provide antigen specificity to a variety of cells, most of which 
are otherwise devoid of antigen recognition structures. The role of these receptors 
trigger effector responses such as cell activation, endocytosis, and phagocytosis. 
The nature of the responses depends primarily on the cell type205. Thus, removal of 
the Fc fragment of antibodies may prevent binding of cells relying on their Fc 
receptors to recognise antigens. 
Activation of complement occurs by three different pathways: the claSSical pathway 
(triggered by IgM or IgG complexed with tissue), the lectin pathway (activated by 
binding mannose-binding lectin to mannose residues on the pathogen surface) and 
the altemative pathway (triggered by spontaneous C3 hydrolysis). The Fc region of 
the IgG or IgM contains a C1 binding site for C1q and binding of C1q to the IgM or 
IgG complexed with tissue activates the classical pathway217. Thus, mitigation with 
Fab and/or F(ab'h fragments may influence the classical pathway but may not be 
enough to mitigate the complement process. 
119 
The Fab and/or F(ab'h fragment treatment under investigation achieved encouraging 
results in vitro despite the lack of in depth optimisation of the polyclonal 
immunoglobulin preparation used to mask IgG binding to the tissue. 
Most treatments of contemporary bioprosthetic heart valves focus on glutaraldehyde 
fixation of the tissue to prevent a host response and provide durability. As 
glutaraldehyde has been reported to be the main villain causing calcification, 
glutaraldehyde concentrations used are suboptimal in terms of their ability to render 
the tissue completely immunogen free. The drive behind alternative fixatives is 
largely geared towards avoiding mineralization of the bioprosthesis, especially in 
children although a decellularisation process is perhaps more focussed on 
minimizing the host response while at the same time offering a scaffold amenable to 
tissue ingrowth and remodelling. This is based on the misconception that cells alone 
are responsible for immunogenicity of bioprosthetic tissue and indeed there are 
studies confirming the significant role that the extracellular matrix plays in 
calcification98 and inflammation218• 219 of bioprosthetic heart valves. 
Our study in fact confirmed that decellularised tissue substantially reduced the 
humoral immune response. Western blotting performed using sera obtained from 
rabbits immunised with decellularised tissue homogenates clearly showed a 
response against porcine aortic wall extract as well as porcine fibronectin. This 
provided support to the concept that cells alone are not responsible for the 
immunogenicity of porcine aortic tissue but that extracellular matrix components 
likewise contribute. Therefore, decellularised tissue, although possibly offering 
ingrowth potential falls short at fully avoiding the problem of immunogenicity. Indeed 
the massive granulocyte response observed in the in vivo study suggests that this is 
possibly due to incomplete antigen washout since bacterial contamination of the 
tissue was discounted (data not shown) and the tissue was also exhaustively washed 
to remove the anionic detergent 50S and other components used in the 
decellularisation process. 
Although the scope of this thesis was to provide proof-of-concept with respect to the 
feasibility of applying immunoglobulin fragments to bioprosthetic tissue by masking 
remnant immunogenicity in contemporary bioprosthetic heart valves, an in vivo pilot 
study designed to investigate whether the concept had at least the potential to 
diminish the inflammatory response as well as identifying logistical problems should 
one endeavour to apply it in patients, was also performed. 
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Also outside of the scope of this thesis, but nevertheless an important consideration 
is the need or not to covalently tether immunoglobulin fragments to the tissue which 
otherwise may only persist for a short duration. 
The source of antibody is of equal importance. Potentially these might involve either 
monoclonal antisera produced in mice or polyclonal ones produced in rabbits. 
Xenogeneic immunoglobulin sources may need to be better evaluated although 
there is a precedence for using animal derived IgG in patients in the clinical organ 
transplant field in the form of the immunosuppressive drug rabbit anti-thymocyte 
globulin (Fresenius)220 produced in rabbits as well as in the murine monoclonal 
antibody OKT3 (Orthokline) also called Muromonab221 • 
Nevertheless, the possibility exists that fragments could, for example be modified 
through a pegylation process whereby polyethylene glycol (PEG) bound to 
immunoglobulin fragments would both serve the purpose of delaying their clearance 
from the blood as well as possibly masking any antigen the pegylated antibody binds 
to with greater efficacy. 
No clear difference was seen between the different groups in the in vivo study 
although the fact that, at least anecdotally, Fab treatment in the decellularised group 
presented with fewer foreign body giant cells. This may be that the as yet suboptimal 
Fab preparation may nevertheless be partly capable of masking the less 
immunogenic decellularised tissue and thereby reduce the response. 
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Appendix A Materials and Methods 
A 1. Isolation of serum 
Animal blood was collected BO Vactuatiner® tubes (cat no 367955) and allowed to 
clot at room temperature. The clotted blood was centrifuged at 1260 xg for 45 
minutes at room temperature and serum collected and stored at -SO°C. 
A2. Isolation of plasma 
Blood were collected in a sterile glass container with the anticoagulant EOTA (0.2 
mglml blood) at the local abattoir (Maitland, Cape Town). The blood was centrifuged 
at 1810 xg for 20 minutes at room temperature, and the plasma collected. The 
plasma was sterile filtered (0.22 J-Im). 
A3. Collect porcine aorta 
Table 3 Phosphate Buffered Saline (PBS) 
Constituent Supplier 
137 mM sodium phosphate Sigma 
3 mM potaSSium chloride Sigma 
2 mM potassium dihydrogen phosphate Sigma 
8 mM sodium phosphate Sigma 
pH 7.4 
Fresh porcine aortas were collected in cold PBS (Table 3) at the local abattoir 
(Maitland, Cape Town, South Africa) from nonnal, healthy pigs. They were 
processed within five minutes of slaughter. After rough dissection, the valves were 
cleaned and rinsed in PBS (Table 3). On arrival at the laboratory the porcine aortas 
were transferred to sterile filtered PBS. 
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A4. Decellularise process (Medtronic) 
Table 4 Wash solution 
Constituent 
0.3% sodium chloride (w/v) 
0.05% sodium azide (w/v) 
20 mM Na2EOTA2H20 








Protease inhibitor cocktail was prepared by adding 1 0 ml deionised water to the 
protease inhibitor cocktail bottle (Sigma, cat. no. P2714). 
Table 5 Decellularise solution 
1"- tituent Supplier 
0.3% sodium chloride (w/v) Sigma 
0.05% sodium azide (w/v) rna 
0.5% SOS (w/v) Sigma 
0.5% Triton X-100 (v/v) Sigma 
pH 7.4 
130 mOsmlkg 
Table 6 Rinse solution 
Constituent Supplier 
0.3% sodium chloride (w/v) Sigma 




Table 7 Sterile solution 
Constituent ~ier 
0.3% sodium chloride (w/v) Sigma 
0.25% CPC (w/v) Sigma 
r 1% IPA (v/v) Sigma 
20 mM Na2EDTA.2H20 Sigma 
pH 7.4 
296 mOsmlkg 
Table 8 Storage solution 
Constituent Supplier 
0.6% Sodium chloride (w/v) Sigma 
0.25% Sodium Azide (w/v) Sigma 
10mM HEPES Sigma 
20 mM EDT A.2H2O Sigma 
pH 7.4 
282 mOsm/kg 
Porcine aortas collected from the abbatoir (see Appendix A3) were cleaned from any 
fat and washed with rolling (60 rpm) for 24 hours at room temperature in wash 
solution (Table 4). The solution was changed from the wash solution to the 
decellularise solution (Table 5). The aortas were washed with rolling (60 rpm) in the 
decellularise solution for 144 hours (6 days) at room temperature. The decellularise 
solution was changed every 24 hours. After decellularising the aortas the solution 
was changed to rinse solution (Table 6). The aortas were washed with rolling (60 
rpm) in the rinse solution for another 144 hours, changing the solution every 0.5 to 1 
hour (at least 40 times). The aortas were sterilised in sterile solution (Table 7) with 
rolling (30 rpm) for 3 hours at room temperature. After sterilisation the aortas were 
stored in storage solution (Table 8) at room temperature until needed. 
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A5. Homogenise tissue 
A stainless steel vial and two bearing balls, as well as a mortar, a pestle and a 
spatula, were cleaned with 70% ethanol and cooled in liquid nitrogen. The tissue 
were cut into smaller pieces and frozen in liquid nitrogen. The frozen tissue pieces 
were placed in the cooled stainless steel vial, with two bearing balls and 
homogenised in a homogeniser for a few seconds (the tissue must stay frozen). 
After all the pieces were homogenised, they were placed in the cooled mortar. liquid 
nitrogen was added and the frozen homogenised powder was mixed and ground with 
the pestle to form a homogeneous mixture. The homogenous powder was frozen in 
liquid nitrogen. freeze-dried overnight and stored at -BO°C. 
A6. Immunisation solutions 
Sterile saline was added to the homogenous powder and vortexed to suspend the 
powder. The Freund's incomplete adjuvant was slowly added to the saline mixture in 
a 1:1 ratio. The two solutions were mixed, using two syringes connected with a small 
tube, to form an emulsion. The thick, white, creamy emulsion was stored at 4°C 
before immunisation. 
A7. Protein extract 
Table 9 Protein extraction Buffer 
Constituent Supplier 
50 mM Tris Sigma 
0.1 % (w/v) sodium dodecylsulfate (SOS) Sigma 
pH 7.4 
Freeze-dried homogenise tissue were weighed and protein extraction buffer (Table 
9) was added in ratio of 100 IJI buffer for 1 mg tissue. The mixture was incubated 
overnight at 4°C. After incubation it was centrifuged at 1260 xg for 15 minutes at 4°C 
and the supernatant was stored at -20°C. 
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AB. DC Protein Assay 
The Bio-Rad DC protein assay is a calorimetric assay for protein concentration. The 
assay is based on the reaction of protein and copper in an alkaline medium and the 
subsequent reduction of Folin reagent by the copper-treated protein. A characteristic 
blue colour develops with maximum absorbance at 750 nm. 
A protein standard (1 mg/ml BSA) (Sigma) was used for the standard curve. 
Doubling dilution series of the protein standard was prepared from 0.625 mglml to 1 
mg/ml in the same buffer as the sample. A doubling dilution series (1 to 64) of the 
sample was also prepared. 100 JJI of the standard dilutions and sample dilutions 
were pipetted into clean, dry test tubes. 500 JJI reagent A (an alkaline copper tartrate 
solution) (Bia-Rad. UK) was added to each tube and vortex. 4 ml reagent B (Folin 
reagent) (Bia-Rad, UK) was added and vortex immediately. After 15 minutes the 
absorbance was read at 750 nm. The standard dilutions series of the known protein 
concentrations of the BSA sample was used to set up a standard curve. The 
absorbance of the samples was used to calculate the concentration of the samples 
using the standard curve. 
A9. SOS Polyacrylamide Gel ElectrophoreSiS (SOS PAGE) 
Table 10 Sample buffer 
Constituent Supplier 
62.5 mM Tris-HCI Sigma 
20% glycerol Sigma 
2% (w/v) SDS Sigma 
pH6.a 
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Table 11 Electrode running buffer 
uent Supplier 
25mM Tris Sigma 
192 mM glycine Sigma 
0.1 % (w/v) SOS Sigma 
pH 8.3 
Table 12 Formulation of SOS-PAGE separation and stacking gels. 
Separation Gel Stacking gel 
Monomer concentration 4% 20% 4% 
acrylamidelbisacrylamide 1.3 ml 6.6ml 1.3ml 
Distilled water 6.1 ml 0.7ml 6.1 ml 
1.5M Tris-HCL. pH 8.8 2.5ml 2.5ml -
0.5M Tris-HCL, pH 6.8 - - 2.5ml 
10% (w/v) SOS 100 IJI 100 IJI 100 IJI 
10% (w/v) ammonium persulfate 50 IJI 50 IJI 50 IJI 
TEMEO 51J1 51J1 10 IJI 
A9a Mini.PROTEAN'> 3 system: 
SOS Page Separation gel solutions for 4% and 20% were prepared (Table 12). The 
gradient gel was poured with the 20% gel solution, while it was diluted with the 4% 
gel solutions. The separation gel was allowed to polymerise before pouring the 4% 
stacking gel. The comb was inserted before the stacking gel was polymerised. After 
the stacking gel was polymerised the comb was removed leaving wells for applying 
the protein samples to the gel. Every gel was run with a molecular weight marker to 
use as a reference for the protein weights. 
The mini-PROTEANe 3 system (Bio-Rad, UK) was used for separating proteins. The 
electrode running buffer (Table 11) was diluted 1:5 with distilled water and poured 
into the upper and bottom buffer chamber. Protein samples were diluted 1:4 in 
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sample buffer (Table 10) and applied to the gel. The mini-gel was run under 
constant voltage (200 V) at room temperature for 45 minutes. 
A 10. Western Blot 
Table 13 Towbin transfer buffer 
Constituent Supplier 
25 mM Tris Sigma 
192 mM glycine Sigma 
20% (vlv) methanol Merck 
0.1 % (w/v) SOS Sigma 
pH 8.3 
Table 14 Tween Tris buffered saline (TIBS) 
Constituent Supplier 
20 mM Tris-HCI Sigma 
500 mM sodium chloride Sigma 
0.05% (vlv) Tween-20 Sigma 
pH 7.5 
The SOS-PAGE gel after the electrophoresis run was equilibrated in Towbin transfer 
buffer (Table 13) for an hour. The PVOF membrane was first activated in 100% 
methanol for a few seconds and then equilibrated with the filter paper in Towbin 
transfer buffer (Table 13). After equilibration the protein was blotted onto PVOF 
membrane using a semi-dry electroblotter (Bio-Rad, UK). The membrane and SOS-
PAGE gel were sandwiched between filter paper. The semi-dry electroblotter was 
run under constant voltage (20 V) for 30 minutes. The membrane was blocked in 5% 
(w/v) milk powder (fat free) TIBS (Table 14) overnight at 4°C with agitation. The 
primary antibody was diluted in 5% (w/v) milk powder (fat free) TIBS (Table 14) and 
the membrane incubated in the milk powder solution for 90 minutes at 3rC. After 
incubation with the primary antibody the membrane was washed three times for 15 
minutes in TIBS (Table 14). The membrane was incubated in horseradish 
peroxidase conjugate secondary antibody diluted in TIBS (Table 14) for 60 minutes 
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at 37°C. After the final three TIBS (Table 14) 15 minutes washes, development of 
bound complex was with Opti-4CN™ Substrate kit (Bio-Rad, UK). The 4-chloro-1-
naphtol forms a brown insoluble chromogenic substrate in the presence of hydrogen 
peroxide. 
A 11. Protein affinity chromatography 
Packing of the column 
The amount of filtration medium needed to fill the column plus an extra 10% was 
equilibrated with twice the column volume of the equilibration buffer. The medium 
was allowed to swell overnight at 4°C. The suspension was degassed for 2 hours 
with periodic swirling. The buffer volume was increased to five times the volume and 
allowed to stand. After the majority of the beads settled the supernatant was 
aspirated to one and half times the settled volume. The column was packed by 
allowing the beads to settle under gravity without air bubbles. One volume of 
equilibration buffer was run through the column. 
Sample application and elution 
Equilibration buffer was added to the sample in a 1:1 ratio and applied to the column. 
After washing the unbound fractions from the column with equilibration buffer, the 
sample was eluted with elution buffer at room temperature with a flow rate of 
0.5ml/min. 1 ml fractions were collected and monitored for its absorbance at 280 nm 
(proteins). The eluted fractions with sample were pooled. 
A11a Protein A-Sepharose column 
Table 15 Equilibration buffer (sodium citrate) 
Constituent Supplier 
50 mM sodium phosphate Sigma 
150 mM sodium chloride Sigma 
5 mM tri-sodium citrate Sigma 
pH 7.4 
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Table 16 Rabbit IgG elution buffer 
Constituent 
200 mM sodium phosphate Sigma 
100 mM citric acid Sigma 
pH 3.0 
Protein A-Sepharose (Sigma) was re-suspended in equilibration buffer (fable 15). 
The suspension was degassed and packed in a column (1 cm x 10 cm) (see -
packing of the column). Sample was applied to the column (see - sample application 
and elution) and IgG was eluted with elution buffer (Table 16). The eluted fractions 
were neutralised with a sodium hydroxide solution to a pH in the region of 7.0-7.4. 
The fractions were pooled and dialysed against PBS (Table 3) overnight at 4°C. 
A 11 b Gelatin-agarose column 
Table 17 Sodium phosphate equilibration buffer 
Constituent Supplier 
M sodium phosphate Sigma 
0.15 M sodium chloride Sigma 
0.005 M tri-sodium citrate 
pH 7.4 
Table 18 Urea elution buffer 
Constituent Supplier 
4 M urea Sigma 
0.05 M Tris-HCI Sigma 
pH 7.5 
Gelatin immobilized on cross-linked 4% beaded agarose (Sigma). was re-suspended 
in sodium phosphate buffer (Table 17). The suspension was degassed and packed 
in a column (1 cm x 20 cm) (see - packing of the column). Sample was applied to the 
column (see sample application and elution) and fibronectin was eluted with elution 
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buffer (Table 16) at room temperature with a flow rate of 0.5 mllmin. The fractions 
were pooled and dialysed against double distilled water overnight at 4°C. 
A11c Fibronectin affinity column 
Prepare fibroneciin affinity column 
Table 19 Coupling buffer 
Constituents 
0.1 M NaHC03 
0.5 M sodium chloride 
pHB.3 
Table 20 Blocking solution 
Constituents 
0.2 M glycine 
Coupling buffer (Table 19) 
pHB.O 
Table 21 Acetate buffer 
Constituents 
0.1 M sodium acetate 










The cyanogen bromide activated sepharose (Sigma, cat no C921 0) was washed with 
cold 1 mM hydrochlOriC acid to remove lactose from the resin and allowed to swell for 
an hour. The resin was washed with double distilled water to remove the lactose 
necessary to stabilise the beads during storage but would interfere with binding if it 
was present during the coupling. After the wash, the resin was activated in the 
coupling buffer (Table 19). Pig plasma fibronectin dissolved in the coupling buffer 
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(Table 19) was added to the resin at a ratio of 10 mg protein per 1 ml of gel. The 
mixture was incubated for 16 hours at 4°C. After incubation the resin was washed 
with the resin activation solution (Table 19). The groups that did not react were 
blocked with blocking solution (Table 20) for 16 hours at 4°C. After blocking the resin 
wash extensively washed five times altemating coupling buffer (Table 19) and 
acetate buffer (Table 21). The resin was degassed and packed in a column (1 cm x 
10 cm) (see packing of the column). The column was equilibrated with equilibration 
buffer (sodium citrate) (Table 15). Equal volume equilibration buffer (sodium Citrate) 
(Table 15) was added to rabbit anti-sera. The mixture was applied to the porcine 
fibronectin column (see sample application and elution). After washing with the 
equilibration buffer, the rabbit IgG was eluted with rabbit IgG elution buffer (Table 
16). at room temperature with a flow rate of 0.5 mUmin. The column output was 
monitored at a wavelength of 280 nm and fractions of 1.0 ml were collected. Sodium 
hydroxide solution was added to the mixture to neutralize the fractions (PH 7.Q..7.4). 
The pooled fractions were dialyzed against PBS (Table 3) ovemight at 4°C. 
A12. Fixation of tissue in glutaraldehyde 
Fresh porcine aortic valves were stored in PBS for 48 hours at 4°C. 
Fresh tissue 
The valves were deposited fixed in 10% formalin and processed for histology (see 
Appendix A18). 
0.2% Glutaraldehyde 
The valves were deposited into cold 0.2% (v:v) glutaraldehyde prepared in PBS 
(Table 3). After 7 days at 4°C the valves were washed in high volume PBS (30 ml/g. 
37°C). The tissue was placed in cold PBS for low volume storage at 4°C until 
needed. 
3% Glutaraldehyde 
The valves were deposited into 3% (v:v) glutaraldehyde prepared in PBS (Table 3). 
After 7 days at 4°C the valves were washed in high volume PBS (30 mUg. 37°C). 
The tissue was placed in cold PBS for low volume storage at 4°C until needed. 
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A 13. Isolation of IgG with PEG 6000 
Table 22 Borate buffer 
Constituent Supplier 
10 mM boric acid Merck 
7.5 mM hydrochloric acid Merck 
37.5 mM sodium chloride Sigma 
pH 8.6 
Two serum volumes of borate buffer (Table 22) were added to rabbit serum. 
Pulverised PEG (Mr 6000) was added to the mixture to give a final concentration of 
15% (w/v). Once the PEG was dissolved the mixture was centrifuged at 12100 g for 
10 minutes at 4°C. The pellet was dissolved in two serum volumes borate buffer, pH 
8.6. Pulverised PEG was added to give a final concentration of 15% (w/v) and once 
dissolved the mixture was centrifuged at 12100 g for 10 minutes at 4°C. The pellet 
was dissolved in half the original serum volume PBS (Table 3), containing 0.05% 
sodium azide and stored at 4°C. 
A 14. Isolation of IgG with sodium sulphate 
4% (w/v) sodium sulphate in PBS (Table 3) was added drop wise with stirring to 
rabbit serum in a 1:1 ratio. After 30 minutes of stirring at room temperature the 
mixture was centrifuged at 2000 g for 30 minutes at room temperature. The pellet 
was dissolved in two serum volumes 2% (w/v) sodium sulphate in PBS (Table 3). 
After 30 minutes of stirring at room temperature the mixture was centrifuged at 2000 
g for 30 minutes at room temperature. The pellet was dissolved in half the original 
serum volume PBS (Table 3), and stored at 4°C. 
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A15. Digestion of IgG with Ficin 
Table 23 Ficin digestion buffer 
Constituent Supplier 
50 mM Tris Sigma 
2 mM EDTA Sigma 
pH 7.0 
IgG was dialysed against Ficin digestion buffer (Table 23). Ficin (Sigma) was added 
in a ratio of 1 :30 (ElS) to IgG and activated by adding L-cysteine to a final 
concentration of either 1 mM (Fab fragments) or 10 mM (F(ab')2 fragments). The 
mixture was incubated at 37°e under gentle shaking and after 3 hours the reaction 
was stopped by adding 1:10 (v/v) of a 100 mM N-ethyl-maleimide solution. The 
mixture was dialysed against PBS (Table 3). 
A16. Digestion of IgG with Pepsin 
Table 24 Acetate buffer 
Constituent 




IgG was dialysed against acetated buffer (Table 24). Pepsin (Sigma) was added in a 
ratio of 1 :20 (ElS) to the rabbit IgG. The mixture was incubated for 8 hours at 37°e 
under gentle shaking and after 8 hours the reaction was stopped by adding 1:10 (v/v) 
of 1 M Tris buffer, pH 8.0. The digestion mixture was dialyzed at 4°e against PBS 
(Table 3). 
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A17. Digestion of IgG with Papain 
Table 25 Papain digestion buffer 
Constituent 






IgG was dialysed against papain digestion buffer (Table 25). Papain (Sigma) was 
added in a ratio of 1 :60 (E/S) to IgG and activated by adding L-cysteine tot a final 
concentration of 1 mM. The mixture was incubated for 8 hours at 37°C under gentle 
shaking and then dialysed at 4°C against PBS (Table 3) 
A18. Conjugate peroxidase to IgG 
IgG was dialysed against PBS (Table 3) without sodium azide (inactivate 
peroxidase). Horseradish peroxidase was added in a ratio of 1:5 (E/S) to the IgG. 
0.02% Glutaraldehyde in PBS, pH 7.4, was added to the mixture to give a final 
concentration of 0.01% Glutaraldehyde and mixed for 1 hour at room temperature. 
Sephadex G-100 (Sigma) was re-suspended in PBS (pH 7.4.) The suspension was 
degassed and packed in a column (1 cm x 30 cm) under gravity (see paragraph A 11 
- packing of the column). 
The IgG peroxidase mixture was applied to the Sephadex G-100 column and eluted 
with PBS (pH 7.4.). 1 ml fractions were collected and monitored at a wavelength of 
280 nm. The peroxidase-lgG conjugate fractions were pooled and stored at 4°C. 
A19. Blocking and processing of samples 
Table 26 Paraformaldehyde 
Constituent Supplier 
4% paraformaldehyde (w/v) Merck 
10M sodium hydroxide Sigma 
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Preparation for 4% paraformaldehyde 
4g paraform was dissolve in 100 ml PBS (Table 3). The solution was heated to 5Boe 
and a few drops 10M sodium hydroxide was added to clear the solution. The 
solution was cooled to room temperature and the pH was adjusted to 7.4. 
Fixing and preparation of sample 
Samples were immersed in 4% paraformaldehyde for 24 hours at room temperature 
to properly fix the tissue. The samples were cut for embedding in wax. 
Wax processing 
The sample was placed in histology cassette and the cassettes were placed into wire 
mesh baskets. The samples were dehydrated through graded alcohols (70%, BO%, 
90% and three solutions of 100% ethanol) for an hour in each solution. The samples 
were cleared in three changes of iso-octane for an hour each time. The samples 
were placed in three changes of paraffin wax at 60°C for an hour in each and 2 hours 
in the last change of paraffin wax. 
Embedding 
The cassette with the sample was removed from the hot paraffin wax and opened. 
The orientation of the sample was determined to correctly embed the sample for 
cutting. The sample was embedded in hot waxed and placed on a cold plate to set 
for 5 to 10 minutes. 
Sectioning of wax block 
The blocks were kept on ice before cutting on a Microtome. The sections were cut 
3JJm thickness. The sections were transferred to a 56°C water bath from where it 
was placed on APES coated slides. The slides were incubated overnight at 37°C to 
dry any water between the sections and slide. 
Dewax sections for staining 
After incubation at 60°C for 30 minutes, the sections were washed three times for 10 
minutes each in 100% xylene changes and three times in 100% alcohol, two times 
96% alcohol and two times in 70% alcohol. After the washes the sections were 
rinsed in fresh tap water. 
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A20. Immunohistochemistry 
Staining of sections with antibodies conjugated to Horseradish Peroxidase (HRP) 
Table 27 0.5% Hydrogen peroxide 
Constituent Supplier 
4 ml hydrogen peroxide UnivAR 
200 ml methanol Sigma 
The sections were treated with 0.5% hydrogen peroxide (Table 27) in methanol for 
10 minutes to block endogenous peroxide in the tissue, washed in fresh tap water 
and placed in nBS (Table 14). All incubations were done in a humidity chamber to 
prevent drying out of the section. The sections were incubated for 1 hour at room 
temperature with primary antibody. Unbound antibody was washed off with nBS 
(Table 14) for 10 minutes. The sections were incubated with secondary antibody for 
1 hour at room temperature. The unbound antibody was washed off with nBS 
(Table 14) for 10 minutes. The sections were incubated with tertiary detection 
antibody conjugated to peroxidase for 30 minutes at room temperature. The 
unbound antibody was washed off with nBS (Table 14) for 10 minutes. Freshly 
prepared DAB (DAKO) solution was added to visualise the bound conjugated 
antibody (brown) and the nuclei were counter-stained with Haematoxylin (blue). 
Mount sections 
The sections were washed in fresh tap water, dehydrated in 100% alcohol and 
cleared in 100% xylene. The sections were mounted in a drop of Entellan on the 
cover slip placed over the section and allowed to dry. 
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A21. Histology 
Haematoxvlin and eosin stain 
Table 28 Mayers haemotoxylin 
Constituent - lier 
2 g haematoxylin Merck 
50 g potassium alum SAARCHEM 
0.2 g sodium iodate Sigma 
1 I double distilled water 
1 g citric acid SAARCHEM I 
50 g chloral hydrate SAARCHEM 
The first four constituents in Table 28 were added and gently heated in a warm bath 
at 37°C. The rest of the constituents were added and boiled for 5 minutes. The 
solution was cooled and filtered and stored in a glass bottle at room temperature. 
Table 29 Acid alcohol 
Constituent Supplier 
1 % concentrated hydrochloric acid Merck 
70% ethanol k 
Table 30 Eosin 
Constituent Supplier 
1 g Eosin Merck 
1 I double distilled water 
Few drops acetic acid Sigma 
The sections were placed in the haematoxylin solution (Table 28) for 5 minutes and 
then 5 minutes in running tap water to stain the nuclei blue. The acid alcohol (Table 
29) was used to differentiate the haematoxylin. The sections were placed in the 
eosin (Table 30) for 30 seconds and dipped in distilled water before mounting the 
sections (see mount sections). 
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Brown and Brenn stain 
The sections was placed in 1 % Crystal violet for 5 minutes and washed in tap water 
to remove the excess crystal violet. The sections were stained in Grams iodine for 5 
minutes and washed in tap water to remove the excess iodine. The slides were 
differentiated in acetone two times for a second and washed in tap water to remove 
acetone. The sections were placed in working basic Fuchsinf or 5 minutes and 
briefly washed in water. The sections were placed in Gallego's solution for 5 minutes 
and washed in tap water. After the sections were washed the sections were dipped 
three times in acetone, three times in Picric acid/acetone, three times in acetone, fIVe 
times in half acetone/xylene, ten times in xylene and finally left for 1 minute in xylene. 
The sections were mounted in DPX. Gram-positive bacteria stained red and Gram-
negative bacteria stain purple. 
ELMAS (Elastic Masson Trichrome) 
Table 31 Verhoeffs solution 
Constituent Supplier 
10% Alcoholic Haem 
10% ferric chloride 
100% iodine 
100% Alcohol Merck 
All the constituents from Table 31 were added in equal quantities. 
Table 32 Acid Fuchsin solution 
Constituent Supplier 
0.5 g Acid Fuchsin 
0.5 ml glacial acetic acid Sigma 
100 ml double distiller water 
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Table 33 Phosphomolybdic acid solution 
Constituent Supplier 
1 g phosphomolybdic. acid 
100ml double distilled water 
Table 34 light green solution 
Constituent Supplier 
2% Light green 
1 % acetic acid Merck 
The sections were mordanted in Bouins fixative for 20 minutes and washed in 
running water for 15 minutes. The sections were covered with Verhoeffs solution 
(Table 31) for 15 minutes and rinsed in water. The sections were differentiate in 2% 
ferric chloride until the excess black was removed, leaving only the elastin stained 
black. The sections were stained with Acid Fuchsin solution (Table 32) for 5 minutes 
and rinsed in water. The sections were stained in phosphomolybdic acid solution 
(Table 33) for 5 minutes and rinsed in water. The sections were lastly stained with 
light green solution (Table 34) for 2 minutes and rinsed in water before mounting 
(see mount sections). The muscle tissue stained red, the collagen stained blue and 
the elastin stained black. 
A22. Transmission electron microscopy 
A22a Fixation of tissue 
Cut the tissue in 2 x 2 x 2 mm and place the tissue in 2.5 % glutaraldehyde (prepared 
in 0.1 M PBS, pH 7.4 (Table 3». The tissue was fixed overnight at 4°C or 1 to 4 
hours at room temperature and after fIXation the tissue was stored at least overnight 
in PBS at 4°C. The tissue was fixed in 2% osmium for 1 to 2 hours in the fume hood 
and rinsed with distilled water for 5 minutes. 
A22b Sample preparation 
The tissue was dehydrated in each of the ethanol solutions for 15 minutes. Firstly in 
50% ethanol, 70% ethanol, 80% ethanol, 90% ethanol and then two times for 20 
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minutes in 100% ethanol. The tissue was then dehydrated twice in 100% acetone 
solutions for 20 minutes each. 
Table 35 Spurr resin 
Constituent Supplier 
10 g vinyl cyclohexene dioxide Sigma 
6 g digilycidyl ether Sigma 
26 g nonenyl succinic anhydride Sigma 
0.4 g dimethylaminoethanol Sigma 
The tissue was prepared for embedding in Spurr resin (Table 35) with different Spurr 
resin ratio solutions in acetone. The tissue was placed in each solution for a hour at 
room temperature. The ratio's (Spurr resin: Acetone) of the solutions were 1 :2. 1: 1 
and 2: 1. The last solution was 100% Spurr resin with two times for 1 hour at room 
temperature. The tissue was embedded in Spur resin in a mould and allowed to 
polymerise overnight at 70oe. 
A22c Immuno-Gold labelling 
Ultra thin sections were cut for gold labelling with an ultramicrotome using a diamond 
knife. The sections where cut 120 nm thin, stretched with choloform vapour and 
collected on 200 to 300 mesh nickel-coated grids. The sections were dried overnight 
before staining. All the solutions and buffers were filterer before use. 
The sections were etched in saturated aqua solution of sodium metaperiodate for 20 
minutes. The grids were washed in distilled water and drained. The grids were 
blocked with normal serum similar to the host species of the secondary antibody 
(gold-labelled) diluted 1 :30 in PBS (Table 3) for 30 minutes. 
Table 36 Washing buffer 
Constituent Supplier 
PBS (Table 3) 
0.1% BSA Sigma 
0.01 % Tween 20 Sigma 
pHB.2 
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The grids were washed in washing buffer (Table 36) for 5 minutes and in distilled 
water. The grids were incubated in primary antibody optimally diluted overnight at 
4Q C. After incubation the grids were washed with PBS, pH 7.2 and were washed 
three times with washing buffer for 5 minutes. The grids were then incubated in the 
secondary goat anit-rabbit immunoglobulin conjugated with gold diluted 1 :50 with the 
washing buffer for 1 to 2 hours at room temperature. After incubation the grids were 
washed in large quantities washing buffer, rinsed in PBS, pH 7.2 and then in distilled 
water. The grids were drained on filter paper and ready for counterstain. 
Table 37 Uranyl acetate 
Constituent Supplier 
2% uranyl acetate dihydrate Sigma 
50% ethanol Sigma 
Store the solution in a dark bottle at 4QC. 
Table 38 Lead citrate 
I Constituent Supplier 
I 
i 2.66 g lead nitrate Sigma 
3.52 g trisodium citrate Sigma 
60 ml distilled water 
16 ml of 10N sodium hydroxide Sigma 
(4 gin 100 ml distilled water) 
Make up to 100 ml with distilled water 
The solution was mixed and filtered before it was stored at 4QC. 
The tissue was stained with uranyl acetate (Table 37) for 10 minutes and afterwards 
with lead citrate (Table 38) for 2 minutes. After staining the grid was immersed in a 
drop of 10% aqua glacial acetic acid for 1 minute and rinsed in distilled water. The 
grid was ready for viewing on the TEM. 
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